Method for treating heart failure with reduced ejection fraction by using dapagliflozin

By using SGLT2 inhibitors such as dapagliflozin, the problem of lower ejaculation fraction in existing heart failure treatment methods was solved, significantly prolonged the time of heart failure events, reduced the incidence of cardiovascular events, and improved the quality of life of patients. Survival time.

CN118948830APending Publication Date: 2024-11-15ASTRAZENECA AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411075455.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2020-03-05
Filing Date
2020-03-09
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing treatments for heart failure have limited effectiveness in reducing ejection fraction, resulting in low five-year survival and high mortality among patients with heart failure, and new treatments are needed to reduce cardiovascular mortality and reduce the occurrence of heart failure events.

Method used

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as dapagliflozin, are used as a treatment for heart failure with reduced ejection fraction, and are administered orally to reduce heart failure symptoms and prolong the time of heart failure events. Reduce the incidence of fatal cardiovascular events and use it in combination with other therapeutic agents to improve therapeutic efficacy.

Benefits of technology

By using SGLT2 inhibitors, the time of heart failure events and fatal cardiovascular events was significantly prolonged, the worsening of heart failure symptoms and event incidence was reduced, the incidence of myocardial infarction and stroke was reduced, and the quality of life of patients was improved. Survival time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The present disclosure relates to methods of treating heart failure with reduced ejection fraction using dapagliflozin. The methods disclosed herein can reduce the risk of complex outcomes of heart failure worsening (first onset of heart failure hospitalization or emergency heart failure treatment) or death due to cardiovascular causes. Each of the three compositions of this composite result, and the total number of death due to heart failure hospitalization and cardiovascular causes, may also be reduced. An SGLT2 inhibitor, such as dapagliflozin, can also reduce the worsening of the symptoms of heart failure. The methods disclosed herein may also improve heart failure symptoms, health conditions, and quality of life.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This case is a divisional application of a patent application with an application date of March 9, 2020, application number 202080000531.4, and invention name “Method for treating heart failure with reduced ejection fraction using dapagliflozin”. Technical Field

[0002] The present invention relates to methods of treating heart failure with reduced ejection fraction using dapagliflozin. Background Art

[0003] Heart failure (HF) is a life-threatening medical condition in which the heart cannot adequately pump enough blood to maintain the body's organs. HF affects approximately 64 million people worldwide (half of whom have reduced ejection fraction (HFrEF)), and the prevalence and incidence of HF continue to rise worldwide. (Cannie DE et al., European Cardiology Review [European Cardiology Review] 14 (2): 89-96 (2019)). HF is a chronic degenerative disease in which half of patients die within five years of diagnosis (Mamas, MA et al., European Journal of Heart Failure [European Journal of Heart Failure] 19: 1095-1104 (2017)). HF is the leading cause of hospitalization for patients over 65 years of age and represents a huge clinical and economic burden (Azad, N. et al., Journal of Geriatric Cardiology [Old Cardiology Journal] 11: 329-337 (2014)).

[0004] The current standard of care treatment paradigm for HF includes the concurrent administration of one or more of the following classes of drugs, such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers, mineralocorticoid receptor agents such as mineralocorticoid receptor antagonists (MRAs), angiotensin receptor neprilysin inhibitors (ARNIs), digoxin, diuretics, heart pump medications, selective sinus node inhibitors, vasodilators, and calcium channel blockers (unless the patient has systolic heart failure). However, even with the best possible treatment, the five-year survival rate for HF is worse than that for most cancers. (Braunwald, E. et al., Lancet 385:812-824 (2015)). The morbidity and mortality of HF patients remains high, and patient outcomes need to be improved. Other methods of treating HF and particularly HFrEF patients are also needed to reduce cardiovascular mortality, reduce heart failure events and worsening of HF symptoms, and improve patient outcomes by slowing the progression of the disease.

[0005] Type 2 sodium-glucose cotransporter (SGLT2) inhibitors are a class of glucose lowering agents that improve blood sugar control at low risk of hypoglycemia independent of insulin secretion, thereby reducing blood pressure, body weight, and uric acid levels (Inzucchi et al., Diabetes & Vascular Dis Res. [Diabetes and Vascular Disease Research] 12 (2): 90-100 (2015)). SGLT2 inhibitors reduce the reabsorption of glucose by the kidneys, which increases the excretion of glucose in the urine (ibid). In addition, SGLT2 inhibitors reduce vascular stiffness and improve endothelial function.

[0006] Dapagliflozin is a potent, highly selective and orally active human renal SGLT2 inhibitor that effectively reduces HbA1c at a low risk of inducing hypoglycemia. Dapagliflozin treatment has been shown to reduce weight, systolic blood pressure, serum uric acid, proteinuria and improve arterial compliance - all conditions associated with increased CV risk (Shigiyama et al., Cardiovasc Diabetol [Cardiovascular Diabetes] 16:84 (2017)). The chemical structure of dapagliflozin is:

[0007]

[0008] Accordingly, the present disclosure relates to methods of treating HFrEF patients, including patients with or without type 2 diabetes (T2D), with an SGLT2 inhibitor, such as dapagliflozin. Summary of the invention

[0009] The present disclosure relates to methods for treating heart failure with reduced ejection fraction (HFrEF) in a patient, comprising administering to the patient an effective amount of a sodium-glucose co-transporter 2 (SGLT2) inhibitor. For example, in some embodiments, the present disclosure includes methods for treating HFrEF in a patient who does not have type 2 diabetes (T2D), comprising administering to the patient an effective amount of a sodium-glucose co-transporter 2 (SGLT2) inhibitor. In other embodiments, the present disclosure includes methods for treating HFrEF in a patient with T2D, comprising administering to the patient an effective amount of a SGLT2 inhibitor.

[0010] Also disclosed are methods of preventing or delaying a fatal cardiovascular event in a patient with HFrEF and with or without T2D, comprising administering to the patient an effective amount of a SGLT2 inhibitor.

[0011] Also disclosed herein is a method for preventing or delaying the onset of diabetes in a patient with HFrEF and without T2D, comprising administering an effective amount of an SGLT2 inhibitor to the patient. In some embodiments, a patient with HFrEF and without T2D has less than 5.7% glycosylated hemoglobin. In some embodiments, a patient with HFrEF and without T2D is a prediabetic patient (i.e., with ≥5.7% and <6.5% glycosylated hemoglobin). In some embodiments, the methods disclosed herein reduce the incidence of T2D relative to placebo. In some embodiments, the methods disclosed herein reduce the incidence of T2D relative to standard HF care agents. In some embodiments, the reduction in the incidence of T2D is measured by the time of the first reported ≥6.5% glycosylated hemoglobin measurement. In some embodiments, the methods disclosed herein result in a hazard ratio of less than 1 for reducing the incidence of T2D relative to placebo. In some embodiments, the methods disclosed herein result in a hazard ratio of less than 1 for reducing the incidence of T2D relative to standard HF care agents.

[0012] Also disclosed is a method for treating HFrEF in a patient with or without T2D, comprising administering to the patient an effective amount of an SGLT2 inhibitor, wherein the patient experiences no adverse events associated with renal dysfunction during treatment. In some embodiments, the absence of adverse events associated with renal dysfunction includes no or minimal decrease in eGFR levels, no end-stage renal disease (ESRD), and / or no death due to renal disease.

[0013] Disclosed herein are methods of reducing the total number of standard heart failure (HF) care agents taken by HFrEF patients with or without T2D, comprising administering to the patient an effective amount of a SGLT2 inhibitor.

[0014] In any embodiment disclosed herein, the SGLT2 inhibitor is dapagliflozin, canagliflozin, empagliflozin, soggliflozin, isogliflozin or erggliflozin, or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof. In at least one embodiment, the SGLT2 inhibitor is dapagliflozin, or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof. In at least one embodiment, dapagliflozin is in a non-crystalline solid form. In at least one embodiment, dapagliflozin is in a crystalline solid form. In at least one embodiment, dapagliflozin is in the form of a (S)-propylene glycol ((S)-PG) solvate having the following structure:

[0015]

[0016] Further disclosed herein is a method comprising administering an effective amount of an SGLT2 inhibitor to a patient in need individually or in combination with at least one other therapeutic agent. In certain embodiments, the other therapeutic agents and the SGLT2 inhibitor are administered in the same or different pharmaceutical compositions and at the same or different times. In certain embodiments, the other therapeutic agents are antidiabetic agents, antiobesity agents, antihyperlipidemic agents, antiatherosclerotic agents, antihypertensive agents, antiplatelet agents, antithrombotic agents or anticoagulant agents. For example, in at least one embodiment, the other therapeutic agents are antidiabetic agents, such as biguanides and / or DPP4 inhibitors. Exemplary biguanides are metformin or its pharmaceutically acceptable salt. Exemplary DPP4 inhibitors include saxagliptin, linagliptin, sitagliptin and its pharmaceutically acceptable salt.

[0017] In the methods disclosed herein, the patient's left ventricular ejection fraction (LVEF) is less than or equal to 40%, such as less than or equal to 35%, 30% or 25%, and in at least one embodiment, is at least 20%. The LVEF can be determined, for example, by using echocardiography, radionuclide ventriculography, contrast angiography, or cardiac MRI.

[0018] In some embodiments, the methods disclosed herein include orally administering to a patient an SGLT2 inhibitor, such as dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof, at a dose of 2.5 mg, 5.0 mg, or 10 mg, once a day. In at least one embodiment, the dose is 10 mg.

[0019] In some embodiments, the methods disclosed herein result in at least one of the following:

[0020] (i) prolonging the time to first heart failure (HF) event and / or fatal cardiovascular event; and / or

[0021] (ii) reduce the severity of heart failure symptoms; and / or

[0022] (iii) reducing the number of heart failure events and / or reducing the incidence of fatal cardiovascular events.

[0023] In some embodiments, the methods disclosed herein reduce the incidence of myocardial infarction. In some embodiments, myocardial infarction is fatal. In some embodiments, myocardial infarction is non-fatal. In some embodiments, the patient has a history of myocardial infarction. In some embodiments, the patient has no history of myocardial infarction. In some embodiments, the methods disclosed herein reduce the incidence of myocardial infarction relative to placebo. In some embodiments, the methods disclosed herein reduce the incidence of myocardial infarction relative to standard HF care agents. In some embodiments, the reduction in the incidence of myocardial infarction is measured by the time to the first fatal or non-fatal myocardial infarction. In some embodiments, the methods disclosed herein result in a hazard ratio of less than 1 for reducing the incidence of myocardial infarction relative to placebo. In some embodiments, the methods disclosed herein result in a hazard ratio of less than 1 for reducing the incidence of myocardial infarction relative to standard HF care agents.

[0024] In some embodiments, the methods disclosed herein reduce the risk of hospitalization for heart failure and cardiovascular death in patients after acute myocardial infarction. In some embodiments, the patient has an acute myocardial infarction within 7 days of starting treatment with an SGLT2 inhibitor. In some embodiments, the patient has a STEMI (ST-segment elevation myocardial infarction). In some embodiments, the patient has a NSTEMI (non-ST-segment elevation myocardial infarction). In some embodiments, the SGLT2 inhibitor is dapagliflozin. In some embodiments, the patient suffers from T2D. In some embodiments, the patient does not suffer from T2D. In some embodiments, the patient suffers from HFrEF. In some embodiments, the patient does not suffer from HFrEF. In some embodiments, relative to placebo, the methods disclosed herein reduce the risk of hospitalization for heart failure and cardiovascular death in patients after acute myocardial infarction. In some embodiments, relative to standard HF care agents, the methods disclosed herein reduce the risk of hospitalization for heart failure and cardiovascular death in patients after acute myocardial infarction. In the methods disclosed herein, the patient to whom the SGLT2 inhibitor is administered may be receiving one or more standard HF care agents before or during the administration of the SGLT2 inhibitor. In some embodiments, the methods disclosed herein produce at least one of the following results in patients with acute myocardial infarction within 7 days:

[0025] (i) prolonging the time to first heart failure (HF) event and / or fatal cardiovascular event; and / or

[0026] (ii) reduce the severity of heart failure symptoms; and / or

[0027] (iii) reduce the number of heart failure events and / or reduce the incidence of fatal cardiovascular events and / or

[0028] (iv) reduce the risk of hospitalization for heart failure and cardiovascular death; and / or

[0029] (v) reduce the risk of fatal or non-fatal myocardial infarction; and / or

[0030] (vi) reduce the risk of major adverse cardiac events (composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke); and / or

[0031] (vii) Reduce the risk of all-cause mortality.

[0032] In some embodiments, the methods described in the above paragraphs result in a hazard ratio of less than 1 for any of (i)-(vii). In some embodiments, the methods disclosed herein result in a hazard ratio of less than 1 relative to patients taking standard HF care. In some embodiments, the methods disclosed herein result in a hazard ratio of less than 1 relative to placebo.

[0033] In some embodiments, the methods disclosed herein reduce the time to the first cardiovascular death event or worsening heart failure symptoms in patients with acute decompensated heart failure. In some embodiments, the patient is hospitalized for worsening heart failure symptoms or acute decompensated heart failure before starting SGLT2 administration. In some embodiments, the patient's left ventricular ejection fraction (LVEF) before starting SGLT2 administration is less than or equal to 40%, for example, less than or equal to 35%, 30% or 25%, and in at least one embodiment, at least 20%. In some embodiments, the SGLT2 inhibitor is dapagliflozin. In some embodiments, the patient suffers from T2D before starting SGLT2 administration. In some embodiments, the patient does not suffer from T2D before starting SGLT2 administration. In some embodiments, the patient's eGFR>30ml / min / 1.73m before starting SGLT2 administration 2. In some embodiments, the patient has increased natriuretic peptides before starting SGLT2 administration. In some embodiments, the patient is hospitalized in a stable state due to worsening heart failure symptoms or acute heart failure. As used herein, "stable state" should be understood to mean at least 24 hours, such as at least 48 hours, such as at least 72 hours before starting SGLT2 administration, and in some embodiments, at least 1 week before starting SGLT2 administration, intravenous diuretics are not increased and intravenous vasodilators or positive inotropes are not used. In some embodiments, the methods disclosed herein reduce the time to the first cardiovascular death event or worsening heart failure symptoms in patients with acute decompensated heart failure relative to placebo. In some embodiments, the methods disclosed herein reduce the time to the first cardiovascular death event or worsening heart failure symptoms in patients with acute decompensated heart failure relative to standard HF care agents. In the methods disclosed herein, patients administered SGLT2 inhibitors may be receiving one or more standard HF care agents before or during the administration of SGLT2 inhibitors.

[0034] In some embodiments, the methods disclosed herein result in at least one of the following outcomes in a patient suffering from acute decompensated heart failure:

[0035] (i) prolong the time to first fatal cardiovascular event; and / or

[0036] (ii) prolongs the time until re-hospitalization for heart failure; and / or

[0037] (iii) increase the time to emergency HF medical attention; and / or

[0038] (iv) prolonging the total number of days alive and discharged from hospital; and / or

[0039] (v) reduce the severity of symptoms of heart failure; and / or

[0040] (vi) Reduce the risk of all-cause mortality.

[0041] In some embodiments, the methods described in the above paragraphs result in a hazard ratio of less than 1 for any of (i)-(vi). In some embodiments, the methods disclosed herein result in a hazard ratio of less than 1 relative to patients taking standard HF care. In some embodiments, the methods disclosed herein result in a hazard ratio of less than 1 relative to placebo.

[0042] In some embodiments, the methods disclosed herein reduce the incidence of any stroke (ischemic, hemorrhagic or uncertain stroke). In some embodiments, the stroke is fatal. In some embodiments, the stroke is non-fatal. In some embodiments, the patient has a history of stroke. In some embodiments, the patient has no history of stroke. In some embodiments, the methods disclosed herein reduce the incidence of stroke relative to placebo. In some embodiments, the methods disclosed herein reduce the incidence of stroke relative to standard HF care agents. In some embodiments, the reduction in the incidence of stroke is measured by the time to the first fatal or non-fatal stroke. In some embodiments, the methods disclosed herein result in a hazard ratio of less than 1 for reducing the incidence of stroke relative to placebo. In some embodiments, the methods disclosed herein result in a hazard ratio of less than 1 for reducing the incidence of stroke relative to standard HF care agents.

[0043] In some embodiments, the administration of SGLT2 inhibitors prolongs the time to the first heart failure (HF) event. In at least one embodiment, the HF event is hospitalized for HF or an emergency HF medical visit. In at least one embodiment, hospitalization for HF includes admission for at least 24 hours in the case of a preliminary diagnosis of HF. In some embodiments, the administration of SGLT2 inhibitors reduces the total number of hospitalizations for HF. In at least one embodiment, the total number of hospitalizations for HF includes first and / or recurrent hospitalizations.

[0044] In some embodiments, hospitalization for HF is attributed to one or more of the following criteria:

[0045] (i) The patient develops new or worsening symptoms of HF; and / or

[0046] (ii) objective evidence of new or worsening HF symptoms; and / or

[0047] (iii) Initiate or intensify HF-specific treatment.

[0048] In at least one embodiment, the patient's new or worsening symptoms of HF include dyspnea, decreased exercise tolerance, fatigue, and / or other symptoms of worsening end-organ perfusion or volume overload. In at least one embodiment, objective evidence of new or worsening symptoms of HF includes physical examination findings that are considered to be attributed to HF and / or laboratory evidence of new or worsening HF. In at least one embodiment, physical examination findings include at least two of the following findings: peripheral edema, increased abdominal distension or ascites, pulmonary rales / crackles / crackles, increased jugular venous pressure and / or hepatojugular venous return, S3 gallop, and / or clinically significant or rapid weight gain associated with fluid retention. In at least one embodiment, laboratory evidence of new or worsening HF includes at least one of the following findings: an increase in B-type natriuretic peptide (BNP) / N-terminal pro-BNP (NT-proBNP) concentration consistent with decompensation of heart failure; radiological evidence of pulmonary congestion; non-invasive diagnostic evidence of clinically significant elevated left or right ventricular filling pressures or low cardiac output or invasive diagnostic evidence in the case of right heart catheterization. In at least one embodiment, initiation or intensification of treatment specifically for HF comprises at least one of: augmentation of oral diuretic therapy, intravenous administration of a diuretic or vasoactive agent, or mechanical or surgical intervention, for example wherein the mechanical or surgical intervention comprises mechanical circulatory support or mechanical fluid removal.

[0049] In some embodiments, an emergency HF medical visit is an emergency room visit for a primary diagnosis of HF, but does not require hospitalization, such as an unplanned emergency visit to a physician's office for a primary diagnosis of HF. In some embodiments requiring an emergency HF medical visit, the patient develops symptoms of HF, and / or has new or worsening physical exam findings and / or laboratory findings of HF. In at least one embodiment, the patient develops one or more symptoms of HF selected from the group consisting of dyspnea, decreased exercise tolerance, fatigue, and / or worsening end-organ perfusion or other symptoms of volume overload. In some embodiments requiring an emergency HF medical visit, the patient initiates or intensifies treatment specifically for HF. In some embodiments requiring an emergency HF medical visit, the patient requires intravenous treatment.

[0050] In some embodiments, administration of an SGLT2 inhibitor prolongs the time to a fatal cardiovascular event.

[0051] In the above-described embodiments, the time to the first heart failure event and / or fatal cardiovascular event can be delayed by 8 weeks to 24 months from the first use of SGLT2 inhibitors. In at least one embodiment, the time to the first heart failure event is delayed by 8 weeks to 24 months from the first use of SGLT2 inhibitors. In at least one embodiment, the time to the fatal cardiovascular event is delayed by 8 weeks to 24 months from the first use of SGLT2 inhibitors.

[0052] In some embodiments, administration of an SGLT2 inhibitor reduces worsening of HF symptoms in the treated patient. In at least one embodiment, the reduction in worsening of heart failure symptoms in the patient lasts for 12-36 months. In at least one embodiment, the reduction in worsening of heart failure symptoms is characterized by a reduction in the number of hospitalizations for HF by the patient. In at least one embodiment, the reduction in worsening of heart failure symptoms is characterized by a reduction in the number of emergency HF medical visits by the patient. In at least one embodiment, the emergency HF medical visit is an emergency room visit or an emergency outpatient medical office visit.

[0053] In at least one embodiment, the mitigation of worsening heart failure symptoms is characterized by a higher score on the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) compared to the patient score before the SGLT2 inhibitor is applied. In such an embodiment, the higher score of KCCQ-TSS occurs within 16 weeks from the start of SGLT2 inhibitor application. In other embodiments, the higher score of KCCQ-TSS occurs within 20 weeks from the start of SGLT2 inhibitor application. In other embodiments, the higher score of KCCQ-TSS occurs within 24 weeks from the start of SGLT2 inhibitor application. In other embodiments, the higher score of KCCQ-TSS occurs within 28 weeks from the start of SGLT2 inhibitor application. In other embodiments, the higher score of KCCQ-TSS occurs within 32 weeks or 8 months from the start of SGLT2 inhibitor application. In at least one embodiment, the higher score of KCCQ-TSS is at least 5 points higher than the score before the SGLT2 inhibitor is applied. In at least one embodiment, the higher score of KCCQ-TSS is at least 10 points higher than the score before the SGLT2 inhibitor is applied. In at least one embodiment, the higher score on the KCCQ-TSS is at least 15 points higher than the score before administration of the SGLT2 inhibitor.

[0054] In some embodiments, administration of the SGLT2 inhibitor results in any one or more of the following:

[0055] a) Relieve symptoms of heart failure;

[0056] b) reduce physical restrictions;

[0057] c) improve athletic performance; and / or

[0058] d) Reduce the amount of sedentary time in daily life.

[0059] In at least one embodiment, the mitigation of heart failure symptoms is characterized in that compared with the patient score before applying the SGLT2 inhibitor, the patient's score on the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) is higher. In such an embodiment, the higher score of KCCQ-TSS occurs within 16 weeks (or 4 months) from the start of SGLT2 inhibitor application. In other embodiments, the higher score of KCCQ-TSS occurs within 20 weeks from the start of SGLT2 inhibitor application. In other embodiments, the higher score of KCCQ-TSS occurs within 24 weeks from the start of SGLT2 inhibitor application. In other embodiments, the higher score of KCCQ-TSS occurs within 28 weeks from the start of SGLT2 inhibitor application. In other embodiments, the higher score of KCCQ-TSS occurs within 32 weeks or 8 months from the start of SGLT2 inhibitor application. In at least one embodiment, the higher score of KCCQ-TSS is at least 5 points higher than the score before the SGLT2 inhibitor application. In at least one embodiment, the higher score on the KCCQ-TSS is at least 10 points higher than the score before the SGLT2 inhibitor is administered. In at least one embodiment, the higher score on the KCCQ-TSS is at least 15 points higher than the score before the SGLT2 inhibitor is administered. In at least one embodiment, the KCCQ-TSS is patient reported, such as in a doctor's office. In at least one embodiment, the patient suffers from T2D. In some embodiments, the patient does not suffer from T2D.

[0060] In at least one embodiment, the reduction of physical limitations is characterized by a higher score on the Kansas City Cardiomyopathy Questionnaire Physical Limitation Score (KCCQ-PLS) compared to the patient score before the SGLT2 inhibitor is applied. In such an embodiment, the higher score of KCCQ-PLS occurs within 16 weeks (or 4 months) from the start of SGLT2 inhibitor application. In other embodiments, the higher score of KCCQ-PLS occurs within 20 weeks from the start of SGLT2 inhibitor application. In other embodiments, the higher score of KCCQ-PLS occurs within 24 weeks from the start of SGLT2 inhibitor application. In other embodiments, the higher score of KCCQ-PLS occurs within 28 weeks from the start of SGLT2 inhibitor application. In other embodiments, the higher score of KCCQ-PLS occurs within 32 weeks or 8 months from the start of SGLT2 inhibitor application. In at least one embodiment, the higher score of KCCQ-PLS is at least 1 point higher than the score before the SGLT2 inhibitor is applied. In at least one embodiment, the higher score of KCCQ-PLS is at least 5 points higher than the score before the SGLT2 inhibitor is applied. In at least one embodiment, the higher score of the KCCQ-PLS is at least 10 points higher than the score before the SGLT2 inhibitor is administered. In at least one embodiment, the higher score of the KCCQ-PLS is at least 15 points higher than the score before the SGLT2 inhibitor is administered. In at least one embodiment, the KCCQ-PLS is patient-reported, such as in a doctor's office. In at least one embodiment, the patient suffers from T2D. In some embodiments, the patient does not suffer from T2D.

[0061] In at least one embodiment, the improvement of exercise capacity is characterized in that compared with the 6MWD of the patient before using the SGLT2 inhibitor, the 6 minute walk distance (6MWD) of the patient is longer. In such an embodiment, a longer 6MWD distance occurs within 16 weeks from the start of SGLT2 inhibitor use. In other embodiments, a longer 6MWD distance occurs within 20 weeks from the start of SGLT2 inhibitor use. In other embodiments, a longer 6MWD distance occurs within 24 weeks from the start of SGLT2 inhibitor use. In other embodiments, a longer 6MWD distance occurs within 28 weeks from the start of SGLT2 inhibitor use. In other embodiments, a longer 6MWD distance occurs within 32 weeks or 8 months from the start of SGLT2 inhibitor use. In at least one embodiment, the improvement of 6 minute walk distance (6MWD) is measured by a distance greater than or equal to 30 meters. In at least one embodiment, the patient suffers from T2D. In certain embodiments, the patient does not suffer from T2D.

[0062] In at least one embodiment, the reduction of sedentary time in daily life is characterized in that the total time spent by the patient in light to vigorous physical activities is increased compared to the time spent by the patient in light to vigorous physical activities before the SGLT2 inhibitor is used. In such embodiments, the reduction of sedentary time in daily life is measured within 7 days after 16 weeks of using the SGLT2 inhibitor and compared with the time spent by the patient in light to vigorous physical activities before the SGLT2 inhibitor is used. In other embodiments, the reduction of sedentary time in daily life is measured within 7 days after 20 weeks of using the SGLT2 inhibitor and compared with the time spent by the patient in light to vigorous physical activities before the SGLT2 inhibitor is used. In other embodiments, the reduction of sedentary time in daily life is measured within 7 days after 24 weeks of using the SGLT2 inhibitor and compared with the time spent by the patient in light to vigorous physical activities before the SGLT2 inhibitor is used. In other embodiments, the reduction of sedentary time in daily life is measured within 7 days after 28 weeks of using the SGLT2 inhibitor and compared with the time spent by the patient in light to vigorous physical activities before the SGLT2 inhibitor is used. In other embodiments, the reduction of sedentary time in daily life is measured within 7 days after 32 weeks or 8 months of administration of SGLT2 inhibitor. In such embodiments, sedentary time in daily life is measured by a wearable activity monitor. In at least one embodiment, the patient suffers from T2D. In certain embodiments, the patient does not suffer from T2D.

[0063] In some embodiments, the administration of SGLT2 inhibitors reduces the number of HF events and / or reduces the incidence of fatal cardiovascular events. In at least one embodiment, the administration of SGLT2 inhibitors reduces the number of HF events. In at least one embodiment, the HF event is hospitalization for HF or emergency HF medical visits. In at least one embodiment, the administration of SGLT2 inhibitors reduces the number of hospitalizations for HF. In at least one embodiment, the administration of SGLT2 inhibitors reduces the number of emergency HF medical visits. In at least one embodiment, emergency HF medical visits are emergency room visits. In at least one embodiment, emergency HF medical visits require intravenous treatment.

[0064] In some embodiments, administration of an SGLT2 inhibitor reduces the composite of hospitalization for HF or a fatal cardiovascular event.

[0065] In the methods disclosed herein, the patient being administered an SGLT2 inhibitor may be receiving one or more standard HF care agents to treat HF ​​before or during administration of the SGLT2 inhibitor. In at least one embodiment, the one or more standard HF care agents are selected from the group consisting of angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers, mineralocorticoid receptor agents such as mineralocorticoid receptor antagonists (MRAs), enkephalinase inhibitors, antiplatelet agents, aspirin, lipid-lowering drugs (e.g., statins, bile acid sequestrants, niacin, fibrates, ω3 fatty acids), and diuretics (e.g., loop diuretics).

[0066] In the methods disclosed herein, the New York Heart Association (NYHA) heart failure classification of the patient administered with the SGLT2 inhibitor is II to IV. In at least one embodiment, the NYHA heart failure classification of the patient administered with the SGLT2 inhibitor is II. In at least one embodiment, the NYHA heart failure classification of the patient administered with the SGLT2 inhibitor is III or IV.

[0067] In the methods disclosed herein, the patient being administered an SGLT2 inhibitor may have an eGFR of ≥30 ml / min / 1.73 m2 prior to administration of the SGLT2 inhibitor. In the methods disclosed herein, the patient being administered an SGLT2 inhibitor may have an eGFR of ≥30 ml / min / 1.73 m2 during administration of the SGLT2 inhibitor. 2 eGFR.

[0068] In the methods disclosed herein, a patient administered a SGLT2 inhibitor may have a plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) level of at least 400 pg / ml, at least 600 pg / ml, or at least 900 pg / ml prior to administration of the SGLT2 inhibitor.

[0069] In the methods disclosed herein, the patient administered the SGLT2 inhibitor may have been medically diagnosed with symptomatic HFrEF prior to administration of the SGLT2 inhibitor. In at least one embodiment, the patient may have been diagnosed with HFrEF for at least two months prior to administration of the SGLT2 inhibitor.

[0070] In the methods disclosed herein, the patient to whom the SGLT2 inhibitor is administered may have suffered from atrial fibrillation and / or atrial flutter before the administration of the SGLT2 inhibitor. In at least one embodiment, the patient to whom the SGLT2 inhibitor is administered does not suffer from atrial fibrillation or atrial flutter before the administration of the SGLT2 inhibitor. In at least one embodiment, the method disclosed herein reduces the incidence of atrial fibrillation in patients with a history of atrial fibrillation or atrial flutter before the administration of the SGLT2 inhibitor. In at least one embodiment, the method disclosed herein reduces the incidence of atrial fibrillation in patients who do not suffer from atrial fibrillation or atrial flutter before the administration of the SGLT2 inhibitor. In some embodiments, the method disclosed herein reduces the incidence of atrial fibrillation relative to placebo. In some embodiments, the method disclosed herein reduces the incidence of atrial fibrillation relative to standard HF care agents. In some embodiments, the reduction in the incidence of atrial fibrillation is measured by the time to the first fatal or non-fatal atrial fibrillation. In some embodiments, the method disclosed herein results in a risk ratio of less than 1 for reducing the incidence of atrial fibrillation relative to placebo. In some embodiments, the method disclosed herein results in a risk ratio of less than 1 for reducing the incidence of atrial fibrillation relative to standard HF care agents.

[0071] In certain embodiments, the disclosed methods result in a reduction in HbA1c in a patient. In certain embodiments, the disclosed methods result in a reduction in systolic blood pressure in a patient. In certain embodiments, the disclosed methods result in a reduction in weight in a patient. In certain embodiments, the disclosed methods result in a reduction in NT-proBNP levels in a patient. In any of the above embodiments, the reduction may occur within 8 months from the start of administration of the SGLT2 inhibitor. In certain embodiments, the disclosed methods result in a reduction in eGFR in a patient over time per ml / min / 1.73 m 2 A sustained decline of 50% or more. In such embodiments, the sustained decline may be for 12 months, 18 months, 24 months or longer.

[0072] In certain embodiments, the methods disclosed herein result in an improvement in NYHA HF classification.

[0073] In certain embodiments, the methods disclosed herein result in a reduction in recurrent hospitalizations for HF or a reduction in recurrent HF events. In at least one embodiment, recurrent HF events include hospitalizations for HF or emergency HF medical visits.

[0074] In certain embodiments, the methods disclosed herein result in a lower incidence of mortality due to non-cardiovascular causes.

[0075] Further disclosed herein is a method for reducing the incidence of the primary composite endpoint of cardiovascular death, HF hospitalization or emergency HF medical visits in HFrEF patients treated with SGLT2 inhibitors and standard HF care agents, wherein the incidence is reduced relative to patients treated with standard HF care agents alone. Further disclosed is a method for reducing the incidence of the secondary composite endpoint of cardiovascular death or HF hospitalization in HFrEF patients treated with SGLT2 inhibitors and standard HF care drugs, wherein the incidence is reduced relative to patients treated with standard HF care agents alone. In any of the above embodiments, the SGLT2 inhibitor can be, for example, dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof. In at least one embodiment, the SGLT2 inhibitor is dapagliflozin, 10 mg orally administered to the patient once a day.

[0076] In some embodiments, the methods disclosed herein result in at least one of the following:

[0077] (i) prolong the time to first heart failure (HF) event and / or fatal cardiovascular event; and / or

[0078] (ii) reduce the severity of heart failure symptoms; and / or

[0079] (iii) reducing the number of heart failure events and / or reducing the incidence of fatal cardiovascular events.

[0080] Also disclosed herein is a method for reducing the risk of hyperkalemia in HF patients, comprising administering an effective amount of an SGLT2 inhibitor to the patient. In some embodiments, the method disclosed herein reduces the risk of hyperkalemia in HF patients, comprising administering to the patient a pharmaceutical composition comprising an effective amount of an SGLT2 inhibitor. In some embodiments, an SGLT2 inhibitor for reducing the risk of hyperkalemia in HF patients is disclosed.

[0081] In some embodiments, the present disclosure relates to a method for reducing the risk of hyperkalemia associated with MRA use in HF patients, comprising administering to the patient an effective amount of an SGLT2 inhibitor. In some embodiments, the present disclosure relates to a method for reducing the risk of hyperkalemia associated with MRA use in HF patients, comprising administering to the patient a pharmaceutical composition comprising an effective amount of an SGLT2 inhibitor. In some embodiments, an SGLT2 inhibitor for reducing the risk of hyperkalemia associated with MRA use in HF patients is disclosed.

[0082] In some embodiments, the present disclosure relates to a method for treating HF in a patient, comprising administering to the patient an effective amount of an MRA and an effective amount of an SGLT2 inhibitor. In some embodiments, the present disclosure relates to a method for treating HF in a patient, comprising administering to the patient a pharmaceutical composition comprising an effective amount of an MRA and an effective amount of an SGLT2 inhibitor. In some embodiments, a combination of an SGLT2 inhibitor and an MRA for reducing the risk of hyperkalemia in a HF patient is disclosed. In some embodiments, an SGLT2 inhibitor for treating HF in a patient is disclosed, wherein the treatment comprises administering to the patient separately, sequentially or simultaneously an MRA and an SGLT2 inhibitor.

[0083] In some embodiments, the SGLT2 inhibitor is dapagliflozin. In some embodiments, the MRA is selected from a steroid mineralocorticoid receptor antagonist (MRA), such as spironolactone (e.g., ) and eplerenone (e.g., In some embodiments, the MRA is selected from nonsteroidal MRAs, such as finerenone, esalidonone, KBP-5074, and apalizone.

[0084] Also disclosed herein is AZD9977, 2-{(3S)-7-fluoro-4-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-3-yl}-N-methylacetamide, which is disclosed in WO 2016 / 001631 and has the following structure:

[0085]

[0086] In some embodiments, a method of treating HF is disclosed, comprising administering to a patient in need thereof an effective amount of AZD9977 or a pharmaceutically acceptable salt thereof; and an effective amount of an SGLT2 inhibitor. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0087] In some embodiments, AZD9977 or a pharmaceutically acceptable salt thereof for use in treating HF in a patient is disclosed, wherein the treatment comprises administering AZD9977 and an SGLT inhibitor to the patient separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0088] In some embodiments, a SGLT2 inhibitor for treating HF in a patient is disclosed, wherein the treatment comprises administering the SGLT2 inhibitor and AZD9977 or a pharmaceutically acceptable salt thereof separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0089] In some embodiments, a method of reducing the risk of hyperkalemia in HF patients is disclosed, comprising administering to a patient in need thereof an effective amount of AZD9977 or a pharmaceutically acceptable salt thereof; and an effective amount of an SGLT2 inhibitor. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0090] In some embodiments, AZD9977 or a pharmaceutically acceptable salt thereof for reducing the risk of hyperkalemia in a HF patient in a patient is disclosed, wherein the treatment comprises administering AZD9977 and an SGLT inhibitor to the patient separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0091] In some embodiments, an SGLT2 inhibitor for reducing the risk of hyperkalemia in HF patients is disclosed, wherein the treatment comprises administering the SGLT2 inhibitor and AZD9977 or a pharmaceutically acceptable salt thereof separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0092] In some embodiments, a method of treating HFrEF is disclosed, comprising administering to a patient in need thereof an effective amount of AZD9977 or a pharmaceutically acceptable salt thereof; and an effective amount of an SGLT2 inhibitor. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0093] In some embodiments, AZD9977 or a pharmaceutically acceptable salt thereof for treating HFrEF in a patient is disclosed, wherein the treatment comprises administering AZD9977 and an SGLT inhibitor to the patient separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0094] In some embodiments, a SGLT2 inhibitor for treating HFrEF in a patient is disclosed, wherein the treatment comprises administering the SGLT2 inhibitor and AZD9977 or a pharmaceutically acceptable salt thereof separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0095] In some embodiments, a method for treating HFpEF is disclosed, comprising administering to a patient in need thereof an effective amount of AZD9977 or a pharmaceutically acceptable salt thereof; and an effective amount of an SGLT2 inhibitor. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0096] In some embodiments, AZD9977 or a pharmaceutically acceptable salt thereof for treating HFpEF in a patient is disclosed, wherein the treatment comprises administering AZD9977 and an SGLT inhibitor to the patient separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0097] In some embodiments, a SGLT2 inhibitor for treating HFpEF in a patient is disclosed, wherein the treatment comprises administering the SGLT2 inhibitor and AZD9977 or a pharmaceutically acceptable salt thereof separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0098] In some embodiments, a method for reducing the risk of cardiovascular death and hospitalization for heart failure is disclosed, comprising administering an effective amount of AZD9977 or a pharmaceutically acceptable salt thereof to a patient in need thereof; and an effective amount of an SGLT2 inhibitor. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0099] In some embodiments, AZD9977 or a pharmaceutically acceptable salt thereof for reducing the risk of cardiovascular death and hospitalization for heart failure in a patient is disclosed, wherein the treatment comprises administering AZD9977 and an SGLT inhibitor to the patient separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0100] In some embodiments, an SGLT2 inhibitor for reducing the risk of cardiovascular death and hospitalization for heart failure in patients is disclosed, wherein the treatment comprises administering the SGLT2 inhibitor and AZD9977 or a pharmaceutically acceptable salt thereof separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0101] In some embodiments, a method for reducing the risk of cardiovascular death and hospitalization for heart failure is disclosed, comprising administering an effective amount of AZD9977 or a pharmaceutically acceptable salt thereof to a patient in need thereof having a LVEF of less than or equal to 55% and an eGFR of about 15-45 ml / min / 1.73 m2; and an effective amount of an SGLT2 inhibitor. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0102] In some embodiments, AZD9977 or a pharmaceutically acceptable salt thereof is disclosed for reducing the risk of cardiovascular death and hospitalization for heart failure in patients with LVEF less than or equal to 55% and eGFR of about 15-45 ml / min / 1.73 m2, wherein the treatment comprises administering AZD9977 and an SGLT inhibitor to the patient separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0103] In some embodiments, an SGLT2 inhibitor for reducing the risk of cardiovascular death and hospitalization for heart failure in patients with LVEF less than or equal to 55% and eGFR of about 15-45 ml / min / 1.73 m2 is disclosed, wherein the treatment comprises administering the SGLT2 inhibitor and AZD9977 or a pharmaceutically acceptable salt thereof separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0104] In some embodiments, a method for reducing the incidence of a composite endpoint of cardiovascular death, hospitalization for heart failure, or emergency HF visits is disclosed, comprising administering an effective amount of AZD9977 or a pharmaceutically acceptable salt thereof to a patient in need thereof having an LVEF of less than or equal to 55% and an eGFR of about 15-45 ml / min / 1.73 m2; and an effective amount of an SGLT2 inhibitor. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex, or prodrug thereof.

[0105] In some embodiments, AZD9977 or a pharmaceutically acceptable salt thereof is disclosed for reducing the incidence of a composite endpoint of cardiovascular death, hospitalization for heart failure or urgent HF visit in patients with LVEF less than or equal to 55% and eGFR of about 15-45 ml / min / 1.73 m2, wherein the treatment comprises administering AZD9977 and an SGLT inhibitor to the patient separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0106] In some embodiments, an SGLT2 inhibitor for reducing the incidence of the composite endpoint of cardiovascular death, hospitalization for heart failure, or urgent HF visit in patients with LVEF less than or equal to 55% and eGFR of approximately 15-45 ml / min / 1.73 m2 is disclosed, wherein the treatment comprises separate, sequential or simultaneous administration of the SGLT2 inhibitor and AZD9977 or a pharmaceutically acceptable salt thereof.

[0107] In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0108] In some embodiments, a method of reducing the incidence of any of all-cause mortality, myocardial infarction or stroke is disclosed, comprising administering an effective amount of AZD9977 or a pharmaceutically acceptable salt thereof to a patient in need thereof having an LVEF of less than or equal to 55% and an eGFR of about 15-45 ml / min / 1.73 m2; and an effective amount of an SGLT2 inhibitor. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0109] In some embodiments, AZD9977 or a pharmaceutically acceptable salt thereof is disclosed for reducing the incidence of any of all-cause mortality, myocardial infarction or stroke in patients with LVEF less than or equal to 55% and eGFR of about 15-45 ml / min / 1.73 m2, wherein the treatment comprises administering AZD9977 and an SGLT inhibitor to the patient separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0110] In some embodiments, an SGLT2 inhibitor for reducing the incidence of any of all-cause mortality, myocardial infarction or stroke in patients with LVEF less than or equal to 55% and eGFR of about 15-45 ml / min / 1.73 m2 is disclosed, wherein the treatment comprises administering the SGLT2 inhibitor and AZD9977 or a pharmaceutically acceptable salt thereof separately, sequentially or simultaneously. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0111] In any of the above embodiments, the SGLT2 inhibitor can be, for example, dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof. In at least one embodiment, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof, administered orally once a day at 10 mg. In any of the above embodiments, AZD9977 or a pharmaceutically acceptable salt thereof is administered orally to the patient once a day in an amount of 100 mg-150 mg.

[0112] In any of the above embodiments, the patient's left ventricular ejection fraction (LVEF) is less than or equal to 40%, such as less than or equal to 35%, 30% or 25%, and in at least one embodiment, at least 20%. In some embodiments, the patient's left ventricular ejection fraction (LVEF) is less than or equal to 40%, such as less than or equal to 35%, 30% or 25%, and in at least one embodiment, at least 20%. In some embodiments, the patient's LVEF is greater than or equal to 40%, such as greater than or equal to 45%, 50% or 55%, and in at least one embodiment, at least 55%. In some embodiments, the patient's eGFR before administration is less than or equal to 45 ml / min / 1.73m2, such as less than or equal to 30 ml / min / 1.73m2, 25 ml / min / 1.73m2, 20 ml / min / 1.73m2 or 1.5 ml / min / 1.73m2. In some embodiments, the patient suffers from T2D. In some embodiments, the patient does not suffer from T2D. In some embodiments, hyperkalemia is understood to refer to a potassium level greater than 5.5 mmol / L. In some embodiments, hyperkalemia may be mild (serum potassium levels greater than 5.5 mmol / L) or moderate / severe (serum potassium levels greater than 6.0 mmol / L). BRIEF DESCRIPTION OF THE DRAWINGS

[0113] Figure 1 is a flow chart describing the screening, randomization, and follow-up of patients in the multicenter Phase 3 clinical trial of dapagliflozin and prevention of adverse outcomes in heart failure (DAPA-HF) described in Example 1. All randomized patients were in the intent-to-treat (ITT) population.

[0114] Figures 2A-2D is a graph depicting cardiovascular results from the DAPA-HF Phase 3 clinical trial (see Example 1). Figure 2A is a graph depicting the composite primary endpoint of the trial: death from cardiovascular causes, hospitalization for heart failure, or urgent heart failure visit requiring intravenous therapy. The primary endpoint ( Figure 2A ), hospitalization for heart failure ( Figure 2B ), death from cardiovascular causes ( Figure 2C ) and death from any cause ( Figure 2D ) with hazard ratios and 95% confidence intervals estimated with the use of Cox regression models, stratified by diabetes status, with history of hospitalization for heart failure and treatment with dapagliflozin or placebo as explanatory variables. Analyses were based on all participants who underwent randomization. Displays were truncated when less than 10% of patients remained at risk. The insets in each figure show the same data on an enlarged y axis.

[0115] Figure 3 A summary of the effects of dapagliflozin on worsening heart failure and mortality from the DAPA-HF Phase 3 clinical trial is provided (see Example 1). The figure shows the primary composite endpoint (which is a composite of death from cardiovascular causes, hospitalization for heart failure, or urgent heart failure visits requiring intravenous treatment) and each of its components. Also shown are narrower composites of death from cardiovascular causes or hospitalization for heart failure and death from any cause, which are secondary outcomes.

[0116] Figure 4 The primary composite results according to pre-specified subgroups from the DAPA-HF Phase 3 clinical trial are described (see Example 1). Race was reported by the investigator. Body mass index (BMI) is weight in kilograms divided by height in meters squared. NYHA = New York Heart Association; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro-B-type natriuretic peptide; MRA = mineralocorticoid receptor antagonist; and eGFR = estimated glomerular filtration rate.

[0117] Figure 5 is a graph depicting baseline KCCQ total symptom score (TSS) divided into three tertiles of (i) ≤ 65.6, (ii) 65.7-87.5, and (iii) > 87.5 points, showing the cumulative percent change within these tertiles over 24 hours from randomization.

[0118] Figure 6Six clinical outcomes were described for patients treated with dapagliflozin versus placebo in the DAPA-HF trial, which included: cardiovascular death, HF hospitalization, or urgent HF visit; cardiovascular death or HF hospitalization; HF hospitalization or urgent HF visit; HF hospitalization; cardiovascular death; and death from any cause.

[0119] Figures 7A-7C The KCCQ Total Symptom Score (TSS) was described after treatment with dapagliflozin compared with placebo in the DAPA-HF trial. Fig. 7A ); KCCQ clinical symptom score (CSS) ( Figure 7B ); and KCCQ Summary Score (OSS) ( Figure 7C )’s picture.

[0120] Figures 8A-8F is a bar graph comparing KCCQ total symptom score (TSS), KCCQ clinical symptom score (CSS), and KCCQ overall summary score (OSS) after treatment with dapagliflozin relative to placebo in the DAPA-HF trial ( Fig. 8A , 8C and 8E) and the corresponding odds ratios (OR) ( Figure 8B , 8D and 8F).

[0121] Figures 9A-9D The primary composite endpoint ( Fig.9A ), the primary composite endpoint—hospitalization for heart failure ( Fig. 9B ), death from cardiovascular causes ( Fig. 9C ) and death from any cause ( Fig.9D ).

[0122] Figures 10A-10B The effects of dapagliflozin compared with placebo on the prespecified primary composite outcome in patients with and without diabetes are depicted according to the glycated hemoglobin level in patients without diabetes at baseline ( Fig. 10A ) and the effects of dapagliflozin compared with placebo on the prespecified primary and secondary composite outcomes, its components, and all-cause mortality according to diabetes status at baseline. Fig. 10B ).

[0123] Figures 11A-11E is a graph depicting the effects of dapagliflozin compared with placebo on laboratory measurements, body weight, and systolic blood pressure according to diabetes status at baseline (i.e., diabetes or no diabetes). Glycated hemoglobin concentration (%) (HbAlc) ( Fig.11A );weight( Fig. 11B ); systolic blood pressure ( Fig. 11C); hematocrit ( Fig.11D ); and creatinine ( Fig.11E ) Change from baseline. Least square mean changes and 95% confidence intervals (CI) are shown. Changes were adjusted for baseline values. *History of diabetes (n=1983) and glycated hemoglobin ≥6.5% at baseline (n=156).

[0124] Figures 12A-12D is a graph depicting the results according to the HbA1c level at baseline, which includes: the main composite outcome ( Fig. 12A ); hospitalization or emergency visit for heart failure ( Fig. 12B ); death from cardiovascular causes ( Fig. 12C ); and death from any cause ( Fig.12D ).

[0125] Fig.13 A responder analysis is depicted showing consistent symptom benefit (e.g., 5 points or more, 10 points or more, 15 points or more) for patients administered dapagliflozin compared to placebo, regardless of threshold KCCQ-TSS score.

[0126] Fig.14 Composite renal outcomes according to diabetes status are described (including 82 dapagliflozin and 74 placebo patients with previously undiagnosed diabetes; i.e., two HbAlc ≥ 6.5% (≥ 48 mmol / mol)), including a sustained decline in eGFR of 50% or greater, end-stage renal disease (defined as persistent eGFR < 15 mL / min / 1.73 rm2), or chronic dialysis or renal transplantation.

[0127] Fig.15 The results showed that the eGFR in patients treated with dapagliflozin increased by 100 mL / min / 1.73 m2 over time compared with patients treated with placebo. 2 of continued decline.

[0128] Fig.16 Describes the change in diabetes per ml / min / 1.73m per year according to diabetes status at baseline 2 eGFR (including 82 dapagliflozin and 74 placebo patients with previously undiagnosed diabetes; i.e., HbA1c ≥ 6.5% (≥ 48 mmol / mol))

[0129] Fig.17 Describes the incidence of new-onset T2D (HbA1c ≥ 6.5%) measured at 2 consecutive study visits after randomization or new T2D reported by the investigator compared with placebo patients with previously undiagnosed diabetes (ie, HbA1c ≥ 6.5%)

[0130] Figures 18A-18BDescribes moderate hyperkalemia (>5.5mmol / L) in patients treated with mineralocorticoid receptor antagonists in the placebo group (non-dashed line) and dapagliflozin group (dashed line) ( Figure 1 8A) and severe hyperkalemia (>6.0mmol / L) ( Fig.18B The cumulative incidence of DETAILED DESCRIPTION

[0131] The present disclosure relates to methods for treating patients with heart failure with reduced ejection fraction (HFrEF), including those with or without type 2 diabetes (T2D), with SGLT2 inhibitors, such as dapagliflozin. The present disclosure also relates to treating HFrEF patients with SGLT2 inhibitors, such as dapagliflozin, by prolonging the time to the first (or recurrent) HF event, alleviating HF symptoms, alleviating the worsening of HF symptoms, and / or reducing the incidence of death from cardiovascular (CV) events. The present disclosure also relates to methods for reducing the incidence of CV death, the primary composite endpoint of HF hospitalization or emergency HF medical visits, or the secondary composite endpoint of CV death or HF hospitalization in HFrEF patients treated with SGLT2 inhibitors and standard HF care agents, wherein the incidence is reduced relative to patients treated with standard HF care agents alone.

[0132] In some embodiments, an SGLT2 inhibitor (eg, dapagliflozin) is administered together with a standard HF care agent (eg, a beta-blocker) in the same or different compositions at the same or different times.

[0133] In some embodiments, the SGLT2 inhibitor (eg, dapagliflozin) is administered together with at least one other therapeutic agent (eg, an antidiabetic agent) in the same or different compositions at the same or different times.

[0134] I. Definitions

[0135] The terms "comprising," "having," "including," and "containing" should be construed as open-ended terms (ie, meaning "including, but not limited to,") unless otherwise noted.

[0136] The term "and / or" as used herein in phrases such as "A and / or B" is intended to include the following embodiments: "A and B", "A or B", "A", and "B".

[0137] Likewise, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to encompass each of the following embodiments: A, B, and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone). Thus, as a practical example, when reference is made to one or more urgent HF events (e.g., HF hospitalizations and / or ER visits) and / or death from cardiovascular causes (which are assessed as endpoints / outcomes following SGLT2 administration), it is intended that the outcome encompasses a composite of all specified events, a composite of any combination of less than all events, or each individual event.

[0138] As used herein, the term "prodrug" refers to, for example, an ester and carbonate that can be converted into an SGLT2 inhibitor under physiological conditions or by solvolysis. Therefore, the term prodrug includes a metabolic precursor of a pharmaceutically acceptable SGLT2 inhibitor. The term prodrug also includes a covalently bound carrier that releases an SGLT2 inhibitor in vivo when the prodrug is applied to a patient. The non-limiting examples of prodrug include reacting one or more hydroxyls of an SGLT2 inhibitor with an acylating agent that is substituted with an alkyl, alkoxy or aryl group using methods known to those skilled in the art to produce esters and carbonates formed with acetate, pivalate, methyl carbonate, benzoate and the like.

[0139] Various forms of prodrugs are known in the art. For examples of such prodrug derivatives, see: (1) Design of Prodrugs, H. Bundgaard, ed., (Elsevier, 1985) and Methods in Enzymology, Vol. 42, pp. 309-396, K. Widder et al., eds. (Academic Press, 1985); (2) A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard, eds., Chapter 5 "Design and Application of Prodrugs," H. Bundgaard, pp. 113-191 (1991); (3) Bundgaard, H., Advanced Drug Delivery, vol. 42, pp. 309-396, K. Widder et al., eds. (Academic Press, 1985); Reviews [Advanced Drug Delivery] 8: 1-38 (1992); (4) Bundgaard, H. et al., Journal of Pharmaceutical Sciences [Pharmaceutical Sciences] 77: 285 (1988); and (5) Kakeya, N. et al., Chem Pharm Bull [Chemical and Pharmaceutical Bulletin] 32: 692 (1984).

[0140] As used herein, the terms "treatment", "treating", etc. refer to measures to cure, slow down, alleviate the symptoms of a diagnosed pathological condition or disorder, such as HFrEF, and / or stop its progression (e.g., administering a drug to a subject). As used herein, patients or subjects who are being or are in need of treatment with an SGLT2 inhibitor as described herein include those diagnosed with a disorder such as HFrEF.

[0141] A "therapeutically effective amount" or "effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result (eg, treating HFrEF).

[0142] Preventive (prophylactic) or defensive (preventative) measures refer to measures (for example, applying SGLT2 inhibitors as described herein to the subject) that prevent and / or slow down the development of target pathological conditions or obstacles. Therefore, those that need preventive or defensive measures include patients with a tendency to suffer from illness and those patients whose illness is to be prevented. "Prevention effective amount" refers to the amount of the prevention result (for example, preventing or delaying fatal cardiovascular events) that effectively achieves the desired effect under necessary dosage and time period.

[0143] The terms "patient" and "subject" are used synonymously to refer to an adult human individual who has been diagnosed with HFrEF and is being treated with standard HF care medications as described herein prior to starting SGLT2 therapy. In some embodiments, the patient has been diagnosed with HFrEF for at least two months.

[0144] As used herein, the term "heart failure with reduced ejection fraction," "HFrEF," or "patient with HFrEF" refers to a chronic medical condition in which the patient's left ventricular ejection fraction (LVEF) is ≤40% and the patient's heart failure symptoms fall within stages II-IV of the New York Heart Association (NYHA) heart failure classification system. See Dolgin M, "Criteria Committee of the New York Heart Association; Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels," 9th ed., Boston, MA: Little Brown & Co (1994). During patient recruitment for the Phase 3 clinical trial described in Example 1, the NYHA heart failure classification system was used. In some embodiments, a "patient with HFrEF" falls within stage II of the NYHA HF classification. In some embodiments, a "patient with HFrEF" falls within stage III or IV of the NYHA HF classification.

[0145] Although in some embodiments, a patient with HFrEF has a left ventricular ejection fraction (LVEF) of less than or equal to 40%, in some embodiments, the LVEF is less than or equal to 35%, 30%, or 25%. In some embodiments, the LVEF is at least 20%. Diagnosis and evaluation of patients with HFrEF typically includes cardiac imaging and physical examination, such as assessment of the LVEF using echocardiography, radionuclide ventriculography, contrast angiography, or cardiac MRI.

[0146] The NYHA HF classification system is based on subjective patient symptom assessments from Class I to Class IV and classifies heart failure based on the patient's ability to function in daily life: Class I: No limitation on physical activity. Normal physical activity does not cause excessive fatigue, palpitations, or dyspnea; Class II. Slight limitation on physical activity. Comfortable at rest. Normal physical activity causes fatigue, palpitations, and dyspnea; Class III. Significant limitation on physical activity. Comfortable at rest. Less than usual activity causes fatigue, palpitations, or dyspnea. Class IV. Discomfort with any physical activity. Symptoms of heart failure occur at rest. Discomfort increases with any physical activity. Patients with NYHA classification stages II-IV were recruited in the Phase III DAPA-HF trial described in Example 1.

[0147] As used herein, "standard HF care agents" include at least one standard HF care agent, for example, at least two or at least three or more drugs or drug classes other than SGLT2 inhibitors, which are used to treat HF, such as HFrEF. Standard HF care agents as described herein may be used before and / or during administration of SGLT2 inhibitors, such as dapagliflozin. Standard HF care drugs and their dosages are well known to cardiologists and other medical practitioners who examine and treat HFrEF patients. Exemplary standard HF care agents include: angiotensin converting enzyme (ACE) inhibitors; angiotensin receptor blockers (ARBs); beta blockers; mineralocorticoid receptor agents such as mineralocorticoid receptor antagonists (MRAs) and enkephalinase inhibitors.

[0148] Other medications that may be used to treat HFrEF and therefore may also be considered “standard HF care” include diuretics and loop diuretics (e.g., furosemide, bumetanide, and torsemide), digoxin, heart pump medications, selective sinus node inhibitors, ivabradine (a sinoatrial (SA) node modulator), aldosterone antagonists, vasodilators, calcium channel blockers (unless the patient has systolic heart failure), hydralazine / isosorbide dinitrate, or other HF medications listed in the practice guidelines. See Yancy CW et al., “ACC / AHA / HFSA focused update of the 2013 ACCF / AHA guideline for the management of heart failure: A report of the American College of Cardiology / American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America,” J Am Coll Cardiol 70(6):776–803 (2017).

[0149] As used herein, the terms "administer", "administering", "administration", etc. refer to methods that can be used to deliver drugs such as SGLT2 inhibitors as described herein. Administration techniques that can be used with the agents and methods described herein can be found, for example, in Goodman and Gilman, The Pharmacological Basis of Therapeutics, current edition, Pergamon; and Remington's, Pharmaceutical Sciences, current edition, Mack Publishing Co., Easton, Pa. In at least one embodiment, the SGLT2 inhibitor is administered orally.

[0150] Administration of an SGLT2 inhibitor "in combination with one or more other therapeutic agents" includes simultaneous (concurrent) or sequential administration at the same or different times and in the same or different pharmaceutical compositions (e.g., pills, tablets, capsules). "Other therapeutic agents" include the standard HF care drugs described above or any other therapeutic agent below, such as antidiabetic agents, antiobesity agents, antihyperlipidemic agents, antiatherosclerotic agents, antihypertensive agents, antiplatelet agents, antithrombotic agents, or anticoagulant agents. "Other therapeutic agents" may be in the form of a pharmaceutically acceptable salt, solvate, mixed solvate, complex, or prodrug.

[0151] In some cases, the additional therapeutic agent is an antidiabetic agent, such as a biguanide (e.g., metformin) and / or a DPP4 inhibitor (e.g., saxagliptin, linagliptin, or sitagliptin). Representative examples of SGLT2 inhibitor + antidiabetic agent combination products include: dapagliflozin / metformin extended release Dapagliflozin / Saxagliptin Dapagliflozin / saxagliptin / metformin Canagliflozin / Metformin Canagliflozin / Metformin ER Empagliflozin / Linagliflozin Empagliflozin / Metformin Empagliflozin / Metformin ER Erpagliflozin / Metformin and erpagliflozin / sitagliptin

[0152] As used herein, "heart failure event" refers to hospitalization for HF and / or emergency HF medical visits.

[0153] As used herein, "hospitalization for HF" or "hospitalization for HF" refers to admission to a hospital for at least 24 hours with a primary diagnosis of HF. In some embodiments, the hospitalized patient presents with new or worsening symptoms due to the onset of HF. In some embodiments, the hospitalized patient has objective evidence of new or worsening HF. In some embodiments, the hospitalized patient initiates or intensifies treatment specifically for HF. In some embodiments, the hospitalized patient has all of the foregoing criteria.

[0154] As used herein, "symptoms attributed to HF" include at least one symptom of dyspnea, decreased exercise tolerance, fatigue, or other symptoms of end-organ perfusion or volume overload. In some embodiments, the symptoms attributed to HF are new or have worsened from a previous medical or hospital visit over a period of time.

[0155] As used herein, "Kansas City Cardiomyopathy Questionnaire (KCCQ)" refers to a questionnaire used by practicing physicians to assess a patient's HF symptoms and / or determine whether a patient's HF symptoms are improving or worsening. The KCCQ uses a scale from 0 to 100, with higher scores indicating fewer HF symptoms, and changes of 5 points or more are clinically significant. See Green, CP, "Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure," J Am Coll Cardiol. [Journal of the American College of Cardiology] 35: 1245-1255 (2000). The KCCQ was administered as an indicator of health-related quality of life (HRQL) in the DAPA-HF clinical trial (Example 1). The analysis in Example 2 showed that dapagliflozin reduced cardiovascular death and HF exacerbation across the entire range of baseline KCCQ values, and improved symptom burden, physical function, and quality of life in HFrEF patients.

[0156] As used herein, "objective evidence of new or worsening HF" refers to physical examination findings and / or laboratory evidence of new or worsening HF that a practicing physician considers to be due to HF. In some embodiments, objective evidence of new or worsening HF consists of at least two physical examination findings. In some embodiments, objective evidence of new or worsening HF consists of one physical examination finding and at least one piece of laboratory evidence.

[0157] As used herein, "physical examination findings thought to be attributable to HF" (including new or worsening HF) refers to at least one of the following findings: peripheral edema; increased abdominal distention or ascites; pulmonary rales / crackles / crackles; increased jugular venous pressure and / or hepatojugular return; S3 gallop; and / or clinically significant or rapid weight gain thought to be related to fluid retention.

[0158] As used herein, "laboratory evidence of new or worsening HF" refers to at least one of the following findings: increased B-type natriuretic peptide (BNP) / N-terminal pro-BNP (NT-proBNP) concentrations consistent with decompensation of heart failure (e.g., BNP >500 pg / mL or NT-proBNP >2,000 pg / mL); radiologic evidence of pulmonary congestion; clinically significant noninvasive evidence of elevated left or right ventricular filling pressures or low cardiac output or invasive evidence in the setting of right heart catheterization showing a pulmonary capillary wedge pressure (pulmonary artery occlusion pressure) ≥18 mm Hg, a central venous pressure ≥12 mm Hg, or a cardiac index <2.2 L / min / m 2 .

[0159] As used herein, "initiation or intensification of HF-specific therapy" refers to at least one of the following: intensification of oral diuretic therapy; intravenous diuretics or vasoactive agents (e.g., inotropes, vasopressors, or vasodilators); mechanical or surgical intervention (e.g., mechanical circulatory support, such as an intra-aortic balloon pump, ventricular assist device, extracorporeal membrane oxygenation, total artificial heart) and / or mechanical fluid removal (e.g., ultrafiltration, hemofiltration, dialysis).

[0160] As used herein, an "urgent HF medical visit" refers to an unplanned urgent medical office visit or emergency department / emergency room visit for a primary diagnosis of HF, but which does not meet the criteria for a HF hospitalization. In some embodiments, the patient in the urgent HF medical visit will have HF symptoms and / or physical exam findings and / or laboratory evidence of new or worsening HF (as described above) and / or initiation or intensification of HF-specific therapy (as described above).

[0161] As used herein, "cardiovascular (CV) death" refers to death in a patient treated with HFrEF as described herein due to the following causes: acute myocardial infarction (MI), sudden cardiac death, heart failure or cardiogenic shock, stroke (cerebrovascular event), cardiovascular surgery, cardiovascular hemorrhage, other cardiovascular causes (referring to CV death that is not included in the above categories but has a specific known cause (e.g., pulmonary embolism or peripheral arterial disease).

[0162] As used herein, "non-cardiovascular (CV) death" refers to any death not covered by "cardiovascular (CV) death."

[0163] As used herein, the term "primary composite outcome" or "primary composite endpoint" refers to the composite of the following HF events as defined above occurring in HFrEF patients taking an SGLT2 inhibitor (e.g., dapagliflozin) in addition to standard HF care:

[0164] Cardiovascular (CV) death;

[0165] Hospitalization for HF; or

[0166] Urgent HF medical visits (defined above to include one or more ER visits and unplanned urgent medical office visits)

[0167] And determine the relative risk reduction in patients taking SGLT2 inhibitors (e.g., dapagliflozin) compared to patients taking standard HF care alone. (See Example 1).

[0168] As used herein, the term "secondary outcome" refers to the composite of the following HF events: CV death or HF hospitalization (as defined above) and determination of the relative risk reduction in patients taking an SGLT2 inhibitor (e.g., dapagliflozin) compared to patients taking standard HF care alone. (See Example 1).

[0169] As used herein, the use of comparative phrases such as "reduction," "was reduced," "worsened," "was decreased," "worsening," "extension," "was extended" in relation to, for example, HF symptoms, HF events, HF hospitalizations, CV death, or non-CV death, is intended to indicate that HFrEF patients taking an SGLT2 inhibitor (e.g., dapagliflozin) are compared to any of the following:

[0170] Patients (or patient groups) not taking SGLT2 inhibitors;

[0171] Patients (or patient groups) taking only standard HF care agents;

[0172] Patients (or groups of patients) who took a placebo during the same time period;

[0173] Patients (or groups of patients) taking placebo and standard HF care during the same time period;

[0174] Patients who have previously received SGLT2 inhibitors;

[0175] Average prognostic expectations for the HFrEF patient population.

[0176] II. SGLT2 inhibitors

[0177] As provided herein, SGLT2 inhibitors can be used in the methods described herein to treat established HFrEF in patients with and without type 2 diabetes.

[0178] Sodium-glucose co-transporter 2 (SGLT2) is a sodium-dependent kidney protein that is responsible for reabsorbing glucose back into the blood. SGLT2 inhibitors (also called "Gliflozins") are a class of drugs that lower blood sugar in patients with type 2 diabetes by inhibiting the kidney SGLT2 protein. As a result, more glucose is excreted in the urine.

[0179] SGLT2 inhibitors that can be used in the disclosed treatment methods for HFrEF patients include dapagliflozin Canagliflozin Empagliflozin Erpagliflozin Sogliflozin, or ipragliflozin, or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug.

[0180] In at least one embodiment, the SGLT2 inhibitor used in the disclosed methods of treating HFrEF patients is dapagliflozin, as described in U.S. Pat. Nos. 6,414,126 and 6,515,117, which are incorporated by reference in their entireties. Approved by the US FDA as a monotherapy in 2014 and then as a combination therapy with diet and exercise in 2017-2019 to improve glycemic control in adults with type 2 diabetes. Dapagliflozin can be administered at a dose of 2.5 mg, 5.0 mg or 10 mg. In at least one embodiment, a dose of 10 mg is administered for use in the disclosed method.

[0181] In some embodiments, "dapagliflozin" refers to the FDA-approved formulation Or it may refer to a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug. In some embodiments, dapagliflozin is in the form of a (S)-propylene glycol ((S)-PG) solvate having the following structure:

[0182]

[0183] In some embodiments, dapagliflozin is in the form of a crystalline solid or a non-crystalline solid.

[0184] In some embodiments, dapagliflozin is formulated as a fixed-dose combination product with another therapeutic agent, such as another antidiabetic agent. and dapagliflozin / saxagliptin and dapagliflozin / saxagliptin / metformin is an example of a combination product containing dapagliflozin.

[0185] III. Standard HF Care Agents

[0186] As used herein, "standard HF care agents" include at least one, e.g., at least two or at least three or more drugs or drug classes other than SGLT2 inhibitors, which are used to treat HF, e.g., HFrEF. Standard HF care agents as described herein may be used before and / or during administration of SGLT2 inhibitors, e.g., dapagliflozin. In some embodiments, standard HF care agents and SGLT2 inhibitors are administered together at the same or different times.

[0187] Exemplary standard HF care agents include: angiotensin converting enzyme (ACE) inhibitors; angiotensin receptor blockers (ARBs); beta blockers; mineralocorticoid receptor agents such as mineralocorticoid receptor antagonists (MRAs) and enkephalinase inhibitors. Standard HF care agents and their dosages are well known to cardiologists and other medical practitioners who examine and treat HFrEF patients. A brief description of these standard HF care agents is as follows:

[0188] ACE inhibitors cause vasodilation in both the venous and arterial systems, so they reduce preload and afterload, increase blood flow to vital organ systems and improve ejection fraction. These drugs also block the enzyme required to convert angiotensin I to angiotensin II. Angiotensin II is a powerful vasoconstrictor that raises blood pressure, releases aldosterone and causes sodium and water retention. ACE inhibitors prevent this cascade of effects. Representative examples of ACE inhibitors include captopril, enalapril and lisinopril.

[0189] Like ACE inhibitors, ARBs block the effects of angiotensin II. ARBs block angiotensin II receptors in blood vessels and adrenal glands. In the blood vessels, ARBs cause dilation of veins and arteries, thereby reducing preload and afterload. Blocking angiotensin II receptors in the adrenal glands reduces the release of aldosterone, thereby increasing the excretion of sodium and water. Representative examples of ARBs include valsartan, losartan, and irbesartan.

[0190] Beta blockers reduce sympathetic nervous system stimulation, lower heart rate and blood pressure and improve left ventricular function, hemodynamics and exercise tolerance. Representative examples of beta blockers include atenolol, propranolol, bisoprolol, carvedilol and extended-release metoprolol.

[0191] Mineralocorticoid receptor antagonists (MRAs) or "aldosterone antagonists" are diuretics that antagonize the effects of aldosterone on mineralocorticoid receptors. This group of drugs is often used in combination with other drugs as an adjunctive therapy for the management of chronic heart failure. Representative examples of MRAs include spironolactone and eplerenone.

[0192] Mineralocorticoid receptor modulator (MRM) is used to describe compounds that exhibit tissue- or cell-specific receptor antagonism (full or partial antagonism).

[0193] Neprilysin inhibitors break down natriuretic peptides, which cause sodium and water loss when the ventricles are overloaded. Delaying their breakdown prolongs their action and removes more sodium and water from the body, reducing intravascular volume and blood pressure, resulting in reduced preload and afterload. A representative example of a neprilysin inhibitor is sacubitril. Neprilysin inhibitors can also be combined with ARBs in a new class of heart failure drugs called angiotensin receptor neprilysin inhibitors. The first-in-class drug sacubitril / valsartan combines an ARB (valsartan) with a neprilysin inhibitor (sacubitril).

[0194] Other medications that can be used to treat HFrEF and therefore may also be considered “standard HF care agents” include diuretics and loop diuretics (e.g., furosemide, bumetanide, and torsemide), digitalis or other heart pump medications, hydralazine / isosorbide dinitrate, ivabradine (a sinoatrial (SA) node modulator), or other HF medications in the practice guidelines. See Yancy CW et al., “ACC / AHA / HFSA focused update of the 2013 ACCF / AHA guideline for the management of heart failure: A report of the American College of Cardiology / American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America,” J Am Coll Cardiol 70(6):776-803 (2017).

[0195] IV. Other Therapeutic Agents

[0196] As described herein, administration of an SGLT2 inhibitor may also be combined with one or more "other therapeutic agents." As used herein, unless the context indicates otherwise, the phrase "other therapeutic agents" generally does not include standard HF care agents as described above.

[0197] Other therapeutic agents that can be used together with the SGLT2 inhibitors described herein include antidiabetic agents, antiobesity agents, antihyperlipidemic agents, antiatherosclerotic agents, antihypertensive agents, antiplatelet agents, antithrombotic agents or anticoagulant agents."Other therapeutic agents" can be in the form of a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug.

[0198] Administration of an SGLT2 inhibitor in combination with one or more "other therapeutic agents" includes simultaneous (concurrent) or sequential administration at the same or different times and in the same or different pharmaceutical compositions (eg, pills, tablets, capsules).

[0199] In some cases, the additional therapeutic agent is an antidiabetic agent, such as a biguanide (e.g., metformin) and / or a DPP4 inhibitor (e.g., saxagliptin, linagliptin, or sitagliptin). Representative examples of SGLT2 inhibitor + antidiabetic agent combination products include: dapagliflozin / metformin extended release Dapagliflozin / Saxagliptin Dapagliflozin / saxagliptin / metformin Canagliflozin / Metformin INVOKAMET ), empagliflozin / linagliptin Empagliflozin / Metformin SYNJARDY ), erpagliflozin / metformin and erpagliflozin / sitagliptin

[0200] V. Methods of treating HFrEF by administering SGLT2 inhibitors

[0201] The present disclosure provides a method of treating HFrEF in a patient, comprising administering to the patient an effective amount of a sodium-glucose co-transporter 2 (SGLT2) inhibitor as described herein. In some embodiments, the patient also suffers from type 2 diabetes. In some embodiments, the patient does not suffer from type 2 diabetes.

[0202] The present disclosure also provides a method of treating HFrEF in a patient who does not have T2D, comprising administering to the patient an effective amount of an SGLT2 inhibitor, wherein the patient does not experience adverse events related to renal dysfunction during the treatment period.

[0203] The present disclosure also provides a method of treating HFrEF in a patient with T2D, comprising administering to the patient an effective amount of an SGLT2 inhibitor, wherein the patient does not experience adverse events related to renal dysfunction during the treatment period.

[0204] In some embodiments, "absence of adverse events related to renal dysfunction" includes no or minimal decrease in the patient's estimated glomerular filtration rate (eGFR) level while on SGLT2 inhibitor therapy, absence of end-stage renal disease (ESRD) and / or absence of death due to renal disease.

[0205] In some embodiments, the SGLT2 inhibitor is dapagliflozin, canagliflozin, empagliflozin, sopagliflozin, ipagliptin or erpagliflozin, or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug.

[0206] In at least one embodiment, the SGLT2 inhibitor is dapagliflozin, or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug. In some embodiments, dapagliflozin is in a non-crystalline solid form. In some embodiments, dapagliflozin is in a crystalline solid form. In some embodiments, dapagliflozin is in the form of a (S)-propylene glycol ((S)-PG) solvate having the following structure:

[0207]

[0208] In some embodiments, SGLT2 inhibitors (e.g., dapagliflozin) are orally administered to patients once a day. In some embodiments, dapagliflozin is administered to patients once a day at a dosage of 2.5 mg, 5.0 mg, or 10 mg. In at least one embodiment, the dosage of dapagliflozin is 10 mg.

[0209] In some embodiments, the method of treating a patient for HFrEF further comprises administering to the patient at least one other therapeutic agent. The other therapeutic agent is administered in the same or different pharmaceutical composition and at the same or different time as the SGLT2 inhibitor.

[0210] In some embodiments, the other therapeutic agent is an anti-diabetic agent, an anti-obesity agent, an anti-hyperlipidemic agent, an anti-atherosclerotic agent, an anti-hypertensive agent, an anti-platelet agent, an anti-thrombotic agent, or an anticoagulant agent.

[0211] In some embodiments, the other therapeutic agent is an antidiabetic agent. In some embodiments, the antidiabetic agent is a biguanide and / or a DPP4 inhibitor. In some embodiments, the biguanide is metformin or a pharmaceutically acceptable salt thereof. In some embodiments, the DPP4 inhibitor is saxagliptin, linagliptin or sitagliptin or a pharmaceutically acceptable salt thereof.

[0212] In some embodiments, the HFrEF patient is receiving one or more standard HF care agents to treat HF ​​prior to or during administration of the SGLT2 inhibitor. In some embodiments, the standard HF care agent is selected from the group consisting of angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers, mineralocorticoid receptor agents such as mineralocorticoid receptor antagonists (MRAs), enkephalinase inhibitors, and diuretics.

[0213] In certain embodiments, at least one of the standard HF care agents is a therapeutically effective amount of an angiotensin converting enzyme (ACE) inhibitor.

[0214] In certain embodiments, at least one of the standard HF care agents is a therapeutically effective amount of an angiotensin II receptor blocker (ARB).

[0215] In certain embodiments, at least one of the standard HF care agents is a beta blocker.

[0216] In certain embodiments, at least one of the standard HF care agents is a mineralocorticoid receptor agent, such as a mineralocorticoid receptor antagonist (MRA).

[0217] In certain embodiments, at least one of the standard HF care agents is a neprilysin inhibitor. In some embodiments, the neprilysin inhibitor is combined with an angiotensin II receptor blocker (eg, sacubitril / valsartan).

[0218] In certain embodiments, at least one of the standard HF care agents is a loop diuretic.

[0219] In some embodiments, administering an SGLT2 inhibitor to a patient results in at least one of the following outcomes:

[0220] (i) prolong the time to first heart failure (HF) event and / or fatal cardiovascular (CV) event; and / or

[0221] (ii) reduce the severity of heart failure symptoms; and / or

[0222] (iii) reducing the number of heart failure events and / or reducing the incidence of fatal cardiovascular events.

[0223] In some embodiments, a "HF event" is a hospitalization for HF or an emergency HF medical visit.

[0224] In some embodiments, hospitalization for HF includes admission to the hospital with a primary diagnosis of HF lasting at least 24 hours.

[0225] In some embodiments, the administration of an SGLT2 inhibitor reduces the total number of hospitalizations for HF. The total number of hospitalizations for HF includes first and / or recurrent hospitalizations.

[0226] In some embodiments, hospitalization for HF is due to one or more of the following criteria: (i) the patient develops new or worsening symptoms of HF; and / or

[0227] (ii) objective evidence of new or worsening HF symptoms; and / or (iii) initiation or intensification of HF-specific therapy. In some embodiments, hospitalization for HF is due to all of the above criteria. In some embodiments, the patient develops new or worsening HF symptoms including dyspnea, decreased exercise tolerance, fatigue, and / or other symptoms of worsening end-organ perfusion or volume overload. In some embodiments,

[0228] Objective evidence of new or worsening HF symptoms includes physical examination findings believed to be attributable to HF and / or laboratory evidence of new or worsening HF. In some embodiments, physical examination findings include at least two of the following findings: peripheral edema, increased abdominal distention or ascites, pulmonary rales / crackles / crackles, increased jugular venous pressure and / or hepatojugular return, S3 gallop, and / or clinically significant or rapid weight gain associated with fluid retention. In some embodiments, laboratory evidence of new or worsening HF includes at least one of the following findings: an increase in B-type natriuretic peptide (BNP) / N-terminal pro-BNP (NT-proBNP) concentration consistent with decompensation of heart failure; radiographic evidence of pulmonary congestion; non-invasive diagnostic evidence of clinically significant elevated left or right ventricular filling pressures or low cardiac output or invasive diagnostic evidence in the setting of right heart catheterization. In some embodiments, the initiation or intensification of treatment specifically for HF includes at least one of the following: augmentation of oral diuretic therapy, intravenous administration of a diuretic or vasoactive agent, or mechanical or surgical intervention. Mechanical or surgical interventions include mechanical circulatory support or mechanical fluid removal.

[0229] In some embodiments, an emergency HF medical visit is an emergency room visit for a preliminary diagnosis of HF, but does not require hospitalization. In some embodiments, an emergency HF medical visit is an unplanned emergency visit to a physician's office for a preliminary diagnosis of HF. In some embodiments, the patient has symptoms of HF, and / or has physical examination findings and / or laboratory findings of new or worsening HF. In some embodiments, the patient has one or more symptoms of HF selected from the group consisting of dyspnea, decreased exercise tolerance, fatigue, and / or worsening end-organ perfusion or other symptoms of volume overload. In some embodiments, the patient starts or intensifies treatment specifically for HF. In some embodiments, the emergency HF medical visit requires intravenous treatment.

[0230] In some embodiments, administration of an SGLT2 inhibitor prolongs the time to a fatal CV event.

[0231] In certain embodiments, the time to the first heart failure event and / or fatal cardiovascular event is delayed by 6 months-24 months from the first time the SGLT2 inhibitor is used. In certain embodiments, the time to the first heart failure event is delayed by 6 months-24 months from the first time the SGLT2 inhibitor is used. In certain embodiments, the time to the fatal cardiovascular event is delayed by 6 months-24 months from the first time the SGLT2 inhibitor is used.

[0232] In some embodiments, administration of an SGLT2 inhibitor reduces worsening of HF symptoms in the treated patient. In some embodiments, the reduction in worsening of heart failure symptoms in the patient lasts for 12-36 months.

[0233] In some embodiments, the reduction in worsening of heart failure symptoms is characterized by a reduction in the number of hospitalizations for HF by the patient. In some embodiments, the reduction in worsening of heart failure symptoms is characterized by a reduction in the number of emergency HF medical visits by the patient. In some embodiments, the emergency HF medical visit is an emergency room visit or an urgent outpatient medical office visit.

[0234] In certain embodiments, the mitigation of heart failure symptom worsening is characterized in that compared with the patient score before using SGLT2 inhibitor, the patient's score on Kansas City Cardiomyopathy Questionnaire (KCCQ) is higher. In certain embodiments, the higher score of KCCQ occurs within 8 months from starting SGLT2 inhibitor to use. In certain embodiments, the higher score of KCCQ is at least 5 points higher than the score before SGLT2 inhibitor uses. In certain embodiments, the higher score of KCCQ is at least 10 points higher than the score before SGLT2 inhibitor uses. In certain embodiments, the higher score of KCCQ is at least 15 points higher than the score before SGLT2 inhibitor uses.

[0235] In some embodiments, the mitigation of worsening heart failure symptoms is characterized by a higher score on the Patient Global Impression of Change (PGIC) questionnaire compared to the patient's score before the SGLT2 inhibitor is administered. In some embodiments, the higher score of the PGIC occurs within 8 months from the start of the SGLT2 inhibitor administration. In some embodiments, the higher score of the PGIC is at least 1 point higher than the score before the SGLT2 inhibitor is administered. In some embodiments, the higher score of the PGIC is at least 2 points higher than the score before the SGLT2 inhibitor is administered. In some embodiments, the higher score of the PGIC is more than 2 points higher than the score before the SGLT2 inhibitor is administered.

[0236] In certain embodiments, the mitigation of heart failure symptom worsening is characterized in that compared with the patient score before using the SGLT2 inhibitor, the patient's score on the patient's overall severity impression (PGIS) questionnaire is higher. In certain embodiments, the higher score of PGIS occurs within 8 months from starting SGLT2 inhibitor to use. In certain embodiments, the higher score of PGIS is at least 1 point higher than the score before the SGLT2 inhibitor uses. In certain embodiments, the higher score of PGIS is at least 2 points higher than the score before the SGLT2 inhibitor uses. In certain embodiments, the higher score of PGIS is more than 2 points higher than the score before the SGLT2 inhibitor uses.

[0237] In some embodiments, administration of a SGLT2 inhibitor reduces the number of HF events and / or reduces the incidence of fatal cardiovascular events.

[0238] In some embodiments, the administration of an SGLT2 inhibitor reduces the number of HF events. In some embodiments, the HF event is a hospitalization for HF or an emergency HF medical visit. In some embodiments, the administration of an SGLT2 inhibitor reduces the number of hospitalizations for HF. In some embodiments, the administration of an SGLT2 inhibitor reduces the number of emergency HF medical visits. In some embodiments, the emergency HF medical visit is an emergency room visit. In some embodiments, the emergency HF medical visit requires intravenous treatment.

[0239] In some embodiments, administration of an SGLT2 inhibitor reduces the incidence of fatal cardiovascular events.

[0240] In some embodiments, administration of an SGLT2 inhibitor reduces the composite of hospitalization for HF or a fatal cardiovascular event.

[0241] In some embodiments, administration of an SGLT2 inhibitor to adults with HFrEF reduces the risk of cardiovascular death and worsening heart failure, and improves heart failure symptoms.

[0242] In some embodiments, the HFrEF patient has an eGFR of ≥30 ml / min / 1.73 m2 prior to administration of the SGLT2 inhibitor. In some embodiments, the HFrEF patient maintains an eGFR of ≥30 ml / min / 1.73 m2 during administration of the SGLT2 inhibitor.

[0243] In some embodiments, the HFrEF patient has a plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) level of at least 400 pg / mL, at least 600 pg / mL, or at least 900 pg / mL prior to administration of the SGLT2 inhibitor.

[0244] In some embodiments, the patient has been medically diagnosed with symptomatic HFrEF prior to administration of the SGLT2 inhibitor. In some embodiments, the patient has been diagnosed with HFrEF for at least two months prior to administration of the SGLT2 inhibitor.

[0245] In some embodiments, the HFrEF patient suffers from atrial fibrillation and / or atrial flutter prior to administration of the SGLT2 inhibitor. In some embodiments, the HFrEF patient does not suffer from atrial fibrillation or atrial flutter prior to administration of the SGLT2 inhibitor. In at least one embodiment, the methods disclosed herein reduce the incidence of atrial fibrillation in HFrEF patients who do not suffer from atrial fibrillation or atrial flutter prior to administration of the SGLT2 inhibitor.

[0246] In some embodiments, administration of an SGLT2 inhibitor reduces HbA1c in a HFrEF patient. In some embodiments, administration of an SGLT2 inhibitor reduces systolic blood pressure in a HFrEF patient. In some embodiments, administration of an SGLT2 inhibitor reduces body weight in a HFrEF patient. In certain embodiments, the disclosed methods result in a reduction in NT-proBNP levels in a patient. In some embodiments, the reduction occurs within 8 months of starting administration of an SGLT2 inhibitor. In certain embodiments, the disclosed methods result in a reduction in eGFR (per ml / min / 1.73 m 2 ) continued to decline.

[0247] In some embodiments, administration of the SGLT2 inhibitor results in improvement in NYHA HF classification.

[0248] In some embodiments, SGLT2 inhibitor administration results in a reduction in recurrent hospitalizations for HF or a reduction in recurrent HF events. In some embodiments, recurrent HF events include hospitalizations for HF or urgent HF medical visits.

[0249] In some embodiments, SGLT2 inhibitor administration results in a lower incidence of all-cause mortality (e.g., death due to cardiovascular causes and non-cardiovascular causes) in patients with or without T2D. In some embodiments, SGLT2 inhibitor administration results in a lower incidence of non-cardiovascular death.

[0250] In another aspect, the present disclosure provides a method for reducing the incidence of the primary composite endpoint of cardiovascular death, HF hospitalization, or emergency HF medical visits in HFrEF patients treated with SGLT2 inhibitors and standard HF care agents, wherein the incidence is reduced relative to patients treated with standard HF care agents alone. In another aspect, the present disclosure provides a method for reducing the incidence of the secondary composite endpoint of cardiovascular death or HF hospitalization in HFrEF patients treated with SGLT2 inhibitors and standard HF care drugs, wherein the incidence is reduced relative to patients treated with standard HF care agents alone. In some embodiments, the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex, or prodrug. In some embodiments, dapagliflozin is administered once daily at 10 mg.

[0251] In another aspect, the present disclosure provides a method of preventing or delaying a fatal CV event in a HFrEF patient without T2D, comprising administering to the patient an effective amount of an SGLT2 inhibitor as described herein.

[0252] The present disclosure also provides a method of preventing or delaying a fatal CV event in a patient with HFrEF and T2D, comprising administering to the patient an effective amount of an SGLT2 inhibitor as described herein.

[0253] In some embodiments, the SGLT2 inhibitor is dapagliflozin Canagliflozin Empagliflozin Erpagliflozin Sogliflozin, or ipragliflozin, or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug.

[0254] In at least one embodiment, as described herein, the SGLT2 inhibitor is dapagliflozin. In some embodiments, dapagliflozin is administered at a dose of 2.5 mg, 5 mg, or 10 mg, once a day. In at least one embodiment, dapagliflozin is administered at a dose of 10 mg, once a day.

[0255] In another aspect, the present disclosure also provides a method of reducing the total number of standard HF care agents taken by a HFrEF patient who does not have T2D, comprising administering to the patient an effective amount of an SGLT2 inhibitor as described herein.

[0256] The present disclosure also provides a method of reducing the total number of standard HF care agents taken by a patient with HFrEF and T2D, comprising administering to the patient an effective amount of a SGLT2 inhibitor.

[0257] In some embodiments, as described herein, administering an effective amount of an SGLT2 inhibitor to a HFrEF patient results in the patient being able to reduce the total number of standard HF care agents that the patient takes. In some embodiments, the total number of standard HF care agents is reduced to 2, 3, or 4. Reducing the total number of standard HF agents that a patient must take can improve health-related quality of life in HFrEF patients with and without TD2.

[0258] The following examples further illustrate the present disclosure, but should of course not be construed as limiting its scope in any way.

[0259] Example 1

[0260] Results of the DAPA-HF Phase III clinical trial

[0261] Introduction

[0262] Large clinical trials involving participants with type 2 diabetes (T2D) have shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure (HF). 1-4 However, it is important to note that the majority of patients in these trials did not have HF at baseline, and the benefit of SGLT2 inhibitor therapy largely reflects the prevention of incident HF. Of note, the reduction in heart failure hospitalizations was observed early after randomization, raising the possibility that one or more mechanisms of action are different from those commonly postulated to explain the cardiovascular benefits of glucose-lowering therapy. 5-9 In addition to the diuretic and associated hemodynamic effects of SGLT2 inhibitors, effects on myocardial metabolism, ion transporters, fibrosis, adipokines, and uric acid have been proposed. 5-9 Most of these effects, along with maintenance of renal function, may also benefit patients with established heart failure, including those without diabetes, in whom SGLT2 inhibitors are not tested. 4,10,11

[0263] The DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) clinical trial was designed to prospectively evaluate the efficacy and safety of the SGLT2 inhibitor dapagliflozin in patients with chronic heart failure and reduced ejection fraction (LVEF ≤ 40%), with and without T2D. 12,13 In this example, results from the DAPA-HF Phase III clinical trial are presented.

[0264] method

[0265] Study Design and Supervision

[0266] AstraZeneca sponsored the trial and collected and analyzed the data. 12,13The trial was conducted and reported according to the protocol and statistical analysis plan. The trial was approved by the ethics committee at each study center. The safety of the patients in the trial was reviewed regularly by an independent data monitoring committee. The sponsor's analysis was reproduced by an independent academic team at the University of Glasgow.

[0267] Study Patients

[0268] Eligibility requirements included age at least 18 years, New York Heart Association (NYHA) class II, III, or IV symptoms, and an ejection fraction of 40% or less. Patients were required to have a plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) level of at least 600 pg / mL, or at least 400 pg / mL if they had been hospitalized for heart failure in the previous 12 months. Patients with atrial fibrillation or atrial flutter on baseline electrocardiogram were required to have an NT-proBNP level of at least 900 pg / mL, regardless of a history of heart failure hospitalization. Patients were required to receive standard medical and device therapy for heart failure, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or sacubitril / valsartan; beta blockers (unless contraindicated or intolerant), and mineralocorticoid receptor (MR) agents (if deemed appropriate). Doses needed to be individually optimized to guideline-recommended targets and stable for at least 4 weeks (except for diuretics, which could be flexibly dosed). The researchers recommended that patients with type 2 diabetes should continue to receive glucose-lowering therapy, but that it can be adjusted as needed. Specifically, the protocol states that the dose of insulin, sulfonylurea therapy, or both can be reduced to minimize the risk of hypoglycemia, for example, in patients with baseline hemoglobin A1C (HbA1c) levels below 7%.

[0269] Exclusion criteria included recent treatment with or intolerance to SGLT2 inhibitors, type 1 diabetes, symptoms of hypotension or systolic blood pressure less than 95 mm Hg, recent worsening heart failure or other cardiovascular events or surgery (or planned surgery), and estimated glomerular filtration rate (eGFR) less than 30 ml / min / 1.73 m 2 body surface area (or rapidly declining renal function).

[0270] Study Procedure

[0271] All patients provided written informed consent and entered a 14-day enrollment period, during which the inclusion and exclusion criteria of the trial were reviewed and baseline information, including findings from clinical examinations and laboratory measurements, was collected. After this period, patients were randomly assigned to receive either 10 mg of dapagliflozin or matching placebo once daily according to an isolated, fixed randomization schedule, using counterbalancing blocks to ensure an approximate 1:1 ratio of the two treatments. Investigators used an interactive voice or web-response system to obtain treatment assignments. Randomization was stratified according to the diagnosis of type 2 diabetes, defined as an HbA1c level of 6.5% or higher (≥48 mmol / mol) confirmed by a central laboratory at the time of the established diagnosis or screening. Patients were evaluated at 14 and 60 days after randomization, with a focus on assessment of heart failure and volume status, adverse events, and examination of renal function and potassium. Further study visits were conducted at 4 months and every 4 months thereafter. The protocol required permanent discontinuation of study medication if gestational or diabetic ketoacidosis occurred. Dose reductions (up to dapagliflozin 5 mg daily or matching placebo) or temporary discontinuation were permitted for any of the acute, unexpected declines in eGFR, volume depletion, or hypotension (or to avoid these), with subsequent dose increases (or restarting of treatment) recommended if possible.

[0272] Study Results

[0273] The primary outcome was a composite of the first episode of worsening heart failure or death from cardiovascular causes. An episode of worsening heart failure was an unplanned hospitalization for heart failure or an urgent heart failure visit requiring intravenous therapy. 14 The first of the secondary outcomes was a composite of heart failure hospitalization or cardiovascular death. Other secondary outcomes were: total number of recurrent heart failure hospitalizations (including repeat admissions) and cardiovascular death; change from baseline to eight months in the total symptom score of the Kansas City Cardiomyopathy Questionnaire (KCCQ) using a 0 to 100 scale, with higher scores indicating fewer symptoms and a change of 5 points or more considered clinically meaningful 15 End-stage renal disease (defined as a sustained decrease in eGFR < 15 mL / min / 1.73 m 2 The incidence of a composite of worsening renal function consisting of 1 year, 5 months, 1 year, or 2 years; 1 year, or 2 years; 2 months, or 3 months; 3 months, or 4 months; 5 months, or 6 months; 7 months, or 8 months; 12

[0274] Outcomes were adjudicated according to prespecified criteria by a clinical end-point committee that was blinded to treatment assignment.

[0275] Statistical analysis

[0276] Preliminary results predicted a hazard ratio (HR) of 0.80 for dapagliflozin compared with placebo. Using a two-sided alpha of 5%, we calculated that 844 primary endpoints would provide 90% statistical power to test this hypothesis. At an expected annual event rate of 11% in the placebo-treated group, it was estimated that approximately 4500 patients would provide the required number of primary events based on an expected recruitment period of 18 months and a mean follow-up period of approximately 24 months. A closed testing procedure was used, including prespecified stratified testing of the primary and secondary endpoints in the order specified above. Type I error was controlled at a two-sided 0.0499 alpha level for multiplicity between primary and secondary endpoints and in view of an interim efficacy analysis.

[0277] Data from all randomly assigned patients were included in the analyses of primary and secondary outcomes according to the intention-to-treat principle. Baseline characteristics were summarized as means and standard deviations, medians and interquartile ranges, or percentages. Longitudinal measures (e.g., glycated hemoglobin level (HbA1c) and body weight) were analyzed with the use of mixed models for repeated measures, and least-squares mean differences between treatment groups with 95% confidence intervals were estimated. Time-to-event data were assessed with the use of Kaplan-Meier estimates and Cox proportional hazards models, stratified according to diabetes status, with history of heart failure hospitalization and treatment as fixed factors (for renal end points, baseline eGFR rather than history of heart failure hospitalization); hazard ratios, 95% confidence intervals, and two-sided P values ​​were calculated with the use of Cox models.

[0278] Total events, including relapse events, were analyzed using semiparametric proportional rate models to test treatment effects and quantify treatment differences. 16

[0279] Using the hierarchical analysis of covariance method, the KCCQ total symptom score was analyzed as a hierarchical composite end point that included patient vital status at 8 months and the change in score from baseline to 8 months in surviving patients, with the corresponding odds ratios used to assess the magnitude of the treatment effect. 17The consistency of the treatment effect was assessed across 14 prespecified subgroups. Prespecified safety analyses included: serious adverse events; adverse events related to discontinuation of study treatment; “adverse events of interest,” i.e., volume depletion, renal events, major hypoglycemic events, fractures, diabetic ketoacidosis, amputation; Fournier gangrene; and laboratory findings of note. No other adverse events were routinely collected, given the large prior collection of safety data for dapagliflozin. Safety analyses were performed in patients who underwent randomization and received at least one dose of dapagliflozin or placebo. Fisher’s exact test was used to compare the incidence of adverse events. Analyses were performed with the use of Stata, version 15 (College Station TX, USA) and R, version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria).

[0280] result

[0281] Study Patients

[0282] From February 15, 2017, to August 17, 2018, 4744 patients were randomly assigned to receive dapagliflozin 10 mg or matching placebo once daily at 410 centers in 20 countries ( Figure 1 At baseline, patient characteristics and heart failure treatment were well balanced between the trial groups (Table 1).

[0283] Table 1: Patient Characteristics at Baseline*

[0284]

[0285]

[0286]

[0287] * Positive and negative values ​​are means ± SD. There were no significant differences between the two groups for any variable.

[0288] Percentages may not total 100 due to rounding.

[0289] ACE denotes angiotensin-converting enzyme, ARB angiotensin receptor blocker, DPP-4 dipeptidyl peptidase 4, GFR glomerular filtration rate, GLP-1 glucagon-like peptide 1, IQR interquartile range, LVEF left ventricular ejection fraction, MRA mineralocorticoid receptor antagonist, N-terminal pro-B-type natriuretic peptide, and NYHA New York Heart Association.

[0290] Race was reported by the investigators.

[0291] §BMI is weight in kilograms divided by height in meters squared.

[0292] An additional 82 patients in the dapagliflozin group and 74 in the placebo group had not been previously diagnosed with diabetes, defined as a glycated hemoglobin level of 6.5% or higher (≥48 mmol / mol) measured in a central laboratory at screening and randomization.

[0293] Among the patients with a history of diabetes at baseline, 993 were in the dapagliflozin group and 990 were in the placebo group.

[0294] Implantable cardioverter-defibrillator or cardiac resynchronization therapy with a defibrillator.

[0295] **Cardiac resynchronization therapy with or without defibrillator.

[0296] Study Drug Administration and Follow-up

[0297] In addition to discontinuations due to death, study drug was discontinued in 249 patients (10.5%) receiving dapagliflozin and 258 patients (10.9%) receiving placebo (P = 0.71). At the last assessment, among patients taking study drug, 2039 (98.1%) in the dapagliflozin group continued to take 10 mg daily; 1993 (98.2%) took an equivalent dose of placebo. At the end of the trial, no patients in the dapagliflozin group and 2 patients in the placebo group had unknown vital status ( Figure 1 The median follow-up time was 18.2 months.

[0298] Study Results

[0299] Worsening heart failure events or death from cardiovascular causes (the primary end point) occurred in 386 patients (16.3%) in the dapagliflozin group and in 502 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001 ( Figure 2A and Table 2 ). Event rates for all three components of the composite outcome favored dapagliflozin; the worst event for heart failure was hospitalization ( Fig. 2 and Table 2 ). Among the patients who received dapagliflozin, 231 (9.7%) were hospitalized for heart failure, as compared with 318 (13.4%) who received placebo (hazard ratio, 0.70; 95% CI, 0.59 to 0.83; P<0.001) ( Figure 2Band Table 2). Death from cardiovascular causes occurred in 227 patients (9.6%) in the dapagliflozin group and in 273 (11.5%) in the placebo group (hazard ratio, 0.82; 95% CI, 0.69 to 0.98; P<0.03) ( Figure 2C and Table 2). During the trial, the number of patients who needed to be treated with dapagliflozin to prevent a primary event was 21.

[0300] Dapagliflozin reduced the secondary composite outcome of hospitalization for heart failure or death from cardiovascular causes (hazard ratio, 0.75; 95% CI, 0.65 to 0.85; P<0.001) (Table 2). There were a total of 567 first and recurrent events in the dapagliflozin group (340 hospitalizations for heart failure and 227 deaths from cardiovascular causes among 382 patients) and 742 events in the placebo group (469 hospitalizations for heart failure and 273 deaths from cardiovascular causes among 495 patients), with an incidence rate ratio of 0.75 (95% CI, 0.65, 0.88; P<0.001) (Table 2).

[0301] The mean increase in KCCQ total symptom score from baseline to month 8 was 6.1±18.6 points in the dapagliflozin group and 3.3±19.2 points in the placebo group (between-group difference, 2.8 points; 95% CI, 1.6 to 4.0 (odds ratio, 1.18; 95% CI, 1.11, 1.26; P<0.001) (Table 2). Compared with placebo, more patients in the dapagliflozin group had an improvement of 5 points or more (58% vs. 51%; odds ratio, 1.15, 95% CI, 1.08, 1.23; P<0.001) and fewer patients had worsening scores (25% vs. 33%; odds ratio, 0.84, 95% CI, 0.78, 0.90; P<0.001).

[0302] The prespecified renal composite outcome occurred in 28 patients taking dapagliflozin (1.2%) and in 39 patients taking placebo (1.6%) (hazard ratio, 0.71; 95% CI, 0.44 to 1.16; P = 0.17) (Table 2).

[0303] A total of 276 patients (11.6%) in the dapagliflozin group and 329 patients (13.9%) in the placebo group died from any cause (hazard ratio, 0.83; 95% CI, 0.71 to 0.97) ( Figure 2D and Table 2). The effects of dapagliflozin on worsening heart failure and death are summarized in Figure 3 middle.

[0304] The effects of dapagliflozin on the primary outcome were generally consistent across prespecified subgroups, including patients without diabetes at baseline, although the benefit appeared to be less in patients with NYHA functional classes III and IV compared with class II ( Figure 4 In a post hoc subgroup analysis of patients taking sacubitril-valsartan at baseline, the hazard ratio for the primary outcome with dapagliflozin versus placebo was 0.75 (95% CI 0.50, 1.13) compared with 0.74 (0.65, 0.86) for patients not taking sacubitril-valsartan.

[0305]

[0306] NA means not applicable, as P values ​​were reported only for outcomes included in the stratified testing strategy, while hazard ratios and 95% confidence intervals (CI) were not reported for outcomes with 10 or fewer events.

[0307] *The primary composite outcome-analysis was time to first occurrence of urgent heart failure visit, hospitalization for heart failure, or death from cardiovascular causes.

[0308] The semiparametric proportional rate model (Lin et al., 2000 16 Total number of heart failure hospitalizations (first and recurrent) and cardiovascular deaths analyzed by the LWYY method - the treatment effect is the incidence rate ratio

[0309] Scores on the Kansas City Cardiomyopathy Questionnaire (KCCQ) range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations related to heart failure. Treatment effects are shown as a win rate. Values ​​greater than 1 indicate superiority.

[0310] Worsening of renal function - composite outcome analysis was the time to first occurrence of a decrease in eGFR of 50% or more lasting at least 28 days, end-stage renal disease (ESRD), or death from renal disease. ESRD is defined as eGFR less than 15 ml / min / 1.73 m 2 Consistent with at least 28 days of treatment, chronic dialysis therapy (lasting at least 28 days), or renal transplantation. Serious adverse events of acute kidney injury: 20 (0.8%) dapagliflozin patients and 41 (1.7%) placebo patients, p=0.007

[0311] / / Safety population included patients who received at least one dose of study drug: dapagliflozin n = 2368 and placebo n = 2368. Numbers reported are patients.

[0312] Severe hypoglycemia was defined as hypoglycemia requiring assistance from another person to actively administer carbohydrates, glucagon, or other corrective measures. All cases occurred in patients with diabetes at baseline.

[0313] **All cases of diabetic ketoacidosis occurred in patients with diabetes at baseline.

[0314] Other results

[0315] Table 3 shows the changes in glycated hemoglobin, hematocrit, plasma potassium, systolic blood pressure, and body weight from baseline to 8 months. The mean creatinine concentration increased from baseline to 2 weeks by 0.08±0.19 mg / dL in the dapagliflozin group and by 0.01±0.17 mg / dL in the placebo group (between-group difference, 0.07 mg / dL; 95% CI, 0.05 to 0.08; P<0.001); the corresponding changes at 8 months were 0.07±0.24 and 0.04±0.25 mg / dL, respectively (difference, 0.02 mg / dL; 95% CI, 0.01 to 0.04; P=0.04). The change in eGFR / ml / min / 1.732 / year from baseline to 720 days was also measured and is shown in Table 3. Fig.15 and 16 middle.

[0316] Table 3: Changes in Weight and Laboratory Variables from Baseline to 8 Months

[0317] (Visit 6)

[0318] variable Dapagliflozin 10mg Placebo Difference between groups (95% CI) HbA1c(%)* -0.21±1.14 0.04±1.29 -0.25 (-0.36 to -0.14), p<0.001 Hematocrit (%) 2.31±3.90 -0.19±3.81 2.49 (2.26 to 2.73), p<0.001 Potassium 0.07±0.53 0.09±0.53 -0.02 (-0.05 to 0.01), p = 0.298 Systolic blood pressure (mm Hg) -1.92±14.92 -0.38±15.27 -1.41 (-2.31 to -0.52), p = 0.002 Weight(kg) -0.88±3.86 0.10±4.09 -0.98 (-1.22 to -0.74), p<0.001 Creatinine mg / dL 14 days 0.08±0.19 0.01±0.17 0.07 (0.05 to 0.08), p<0.001 8 months 0.07±0.24 0.04±0.25 0.02 (0.01 to 0.04), p = 0.001

[0319] *Calculated only in patients with diabetes at baseline.

[0320] Security

[0321] Prespecified safety results of particular interest are shown in Table 2. Five patients assigned to dapagliflozin and 3 patients assigned to placebo did not receive study treatment and were therefore excluded from the safety analysis. Adverse events related to volume depletion occurred in 178 patients (7.5%) in the dapagliflozin-treated group and in 162 patients (6.8%) assigned to placebo (P = 0.40). Serious adverse events related to volume depletion occurred in 29 patients (1.2%) treated with dapagliflozin and in 40 patients (1.7%) in the placebo group (P = 0.23).

[0322] Adverse events related to renal dysfunction occurred in 153 patients (6.5%) in the dapagliflozin group and in 170 patients (7.2%) in the control group (P = 0.36) (Table 2). Serious renal adverse events occurred in 38 patients (1.6%) treated with dapagliflozin and in 65 patients (2.7%) in the placebo group (P = 0.009).

[0323] Adverse events rarely required treatment interruption (Table 2). Lower limb amputations and fractures were rare in both treatment groups, with similar incidences of each condition (Table 2). Severe hypoglycemia (four patients in the dapagliflozin group and four in the placebo group) and diabetic ketoacidosis (three versus zero) were also uncommon (Table 2). No cases of Fournier gangrene were reported in the dapagliflozin group and one in the placebo group. No serious adverse events (SAEs) of apparent overdose occurred in the dapagliflozin group.

[0324] discuss

[0325] In this multicenter, randomized, placebo-controlled trial of patients with chronic heart failure with reduced left ventricular ejection fraction, dapagliflozin reduced the risk of the primary composite outcome of the first episode of worsening heart failure (hospitalization for heart failure or urgent heart failure visit requiring intravenous treatment) or death from cardiovascular causes. Each of the three components of this outcome was reduced, and the total number of hospitalizations for heart failure and deaths from cardiovascular causes was also reduced. Dapagliflozin also improved heart failure symptoms, as measured by the total symptom score of the Kansas City Cardiomyopathy Questionnaire (KCCQ). The observed benefits, which are substantial and clinically important, occurred early after randomization and were obtained in participants who received recommended background treatment for heart failure in a high proportion of patients, including renin-angiotensin system blockers, beta blockers, and mineralocorticoid receptor antagonists.

[0326] Notably, dapagliflozin was as effective in the 55% of patients without type 2 diabetes as in the participants with diabetes. This first demonstration of cardiovascular benefits of SGLT2 inhibitors in patients without diabetes supports previous suggestions that such treatments may have beneficial effects beyond glucose lowering. 4-11 Therefore, the discovery of DAPA-HF may expand the therapeutic effect of dapagliflozin beyond diabetes.

[0327] The reduction in the primary outcome was generally consistent across the remaining prespecified subgroups, although one subgroup suggested possible heterogeneity in the treatment effect, with patients with NYHA function classes III and IV benefiting less compared with class II. However, other subgroups also reflected more advanced disease, such as lower ejection fraction, worse renal function, and higher NT-proBNP, which was inconsistent with the findings by NYHA class.

[0328] The population studied in the DAPA-HF trial is quite different from previous SGLT2 inhibitor trials, namely, DAPA-HF patients are at higher risk for hospitalization for heart failure and death from cardiovascular causes. Most are already treated with loop diuretics and mineralocorticoid receptor antagonists, and it is not known whether dapagliflozin will cause the initial natriuresis and diuresis expected in other patient groups. It is believed that this effect may lead to volume depletion and worsening of renal function, especially as many of our patients have chronic kidney disease. Neither adverse reaction was found to be common (each effect occurred in less than 8% of patients in either treatment group), and serious renal adverse events were generally uncommon, with a significantly lower frequency in the dapagliflozin group. Overall, a small number of patients discontinued study treatment due to any adverse reaction (less than 5% of patients in either treatment group). Severe hypoglycemia was rare, as was diabetic ketoacidosis, with all cases of both adverse events occurring in patients with diabetes.

[0329] Baseline use of sacubitril-valsartan, which is more effective than renin-angiotensin system blockade alone in reducing heart failure hospitalizations and death from cardiovascular causes, was low. 18 However, the mechanisms of action of SGLT2 inhibition and neprilysin inhibition are presumed to be different, and in a post hoc subgroup analysis, the benefit of dapagliflozin was similar in patients treated with and without sacubitril–valsartan. 19,20

[0330] In conclusion, among patients with heart failure and reduced ejection fraction, including those without type 2 diabetes, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure and death from cardiovascular causes and improved symptoms.

[0331] References:

[0332] 1 Zinman B. et al., "Empagliflozin, Cardiovascular Outcomes, and Mortalityin Type 2Diabetes," N Engl J Med. 373(22):2117-2128(2015).

[0333] 2Neal B.et al.,“Canagliflozin and Cardiovascular and Renal Events inType 2Diabetes,”N Engl J Med.377(7):644-657(2017).

[0334] 3 Wiviott S.D.et al.,“Dapagliflozin and Cardiovascular Outcomes inType 2Diabetes,N Engl J Med.380:347-357(2019).

[0335] 4 Perkovic V.et al.,Canagliflozin and Renal Outcomes in Type 2Diabetesand Nephropathy,N Engl J Med.380:2295-2306(2019).

[0336] 5 Packer M.et al.,“Effects of Sodium-Glucose Cotransporter 2Inhibitorsfor the Treatment of Patients With Heart Failure:Proposal of a NovelMechanism of Action,”JAMACardiol.2(9):1025-1029(2017).

[0337] 6 Verma S.and McMurray J.J.V.,“SGLT2 inhibitors and mechanisms ofcardiovascular benefit:a state-of-the-art review,”Diabetologia 61(10):2108-2117(2018).

[0338] 7Inzucchi S.E.et al.,“Improvement in Cardiovascular Outcomes WithEmpagliflozin Is Independent of Glycemic Control,”Circulation 138(17):1904-1907(2018).

[0339] 8 Lytvyn Y.et al.,“Sodium Glucose Cotransporter-2 Inhibition in HeartFailure:Potential Mechanisms,Clinical Applications,and Summary ofClinicalTrials,”Circulation 136(17):1643-1658(2017).

[0340] 9 Bonnet F.and Scheen A.J.,“Effects of SGLT2 inhibitors on systemicand tissuelow-grade inflammation:The potential contribution to diabetescomplications andcardiovascular disease,”Diabetes Metab.44:457-464(2018).

[0341] 10 Wanner C.et al.,“Empagliflozin and Progression of Kidney Disease inType 2Diabetes,”N Engl J Med.375:323-334(2016).

[0342] 11Zelniker T.A.et al.,“SGLT2 inhibitors for primary and secondaryprevention ofcardiovascular and renal outcomes in type 2 diabetes:asystematic review andmeta-analysis of cardiovascular outcome trials,”Lancet393:31-39(2019).

[0343] 12 McMurray J.J.V.et al.,“DAPA-HF design paper-A trial to evaluate theeffect ofthe sodium glucose co-transporter 2 inhibitor dapagliflozin onmorbidity and mortality inpatients with heart failure and reduced leftventricular ejection fraction(DAPA-HF),Eur JHeart Fail.21:665-675(2019).

[0344] 13 McMurray J.J.V.et al.,“The Dapagliflozin and Prevention of Adverse-Outcomesin Heart Failure(DAPA-HF)trial:baseline characteristics,”Eur J HeartFail.,doi:10.1002 / ejhf.1548.[Epub ahead of print](2019 Jul 15).

[0345] 14Hicks K.A.et al.,“Standardized Data Collection for CardiovascularTrialsInitiative(SCTI)2017 Cardiovascular and Stroke Endpoint Definitions forClinicalTrials,”Circulation 137:961-972(2018).

[0346] 15 Green C.P.,“Development and evaluation of the Kansas CityCardiomyopathyQuestionnaire:a new health status measure for heart failure,”JAm Coll Cardiol.35:1245-1255(2000).

[0347] 16 Lin D.Y.et al.,“Semiparametric regression for the mean and ratefunctions ofrecurrent events,”J R Stat Soc Series B Stat Methodol 62:711-730(2000).

[0348] 17 Wang D.and Pocock S.,“A win ratio approach to comparing continuousnon-normal outcomes in clinical trials.”Pharm Stat.15:238-245(2016).

[0349] 18 McMurray J.J.et al.,“Angiotensin-neprilysin inhibition versusenalapril in heart failure,”N Engl J Med.371:993-1004(2014).

[0350] 19McMurray JJ, "Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances," Eur JHeart Fail. 17: 242-247 (201 5).

[0351] 20 Packer M., "Reconceptualization of the Molecular Mechanism by WhichSodium-Glucose Cotransporter 2Inhibitors Reduce the Risk of Heart Failure Events," Circulation 140: 443-445 (2019).

[0352] Example 2

[0353] Results of the DAPA-HF Phase III clinical trial: Effects of dapagliflozin on HF symptoms, health status, and quality of life

[0354] Introduction

[0355] Patients with HF and HFrEF are at high risk for disease progression, leading to clinical deterioration, rehospitalization, and death. Bui, AL, et al., Nat Rev Cardiol 8:30-41 (2011). Importantly, they also bear a heavy burden of debilitating symptoms that impact their daily function and quality of life. Indeed, some treatments for HFrEF have a positive effect on death and hospitalization but do not improve health status (Reddy, P. and Dunn, AB, Pharmacotherapy 20:679-689 (2000), which highlights the high unmet need for additional effective therapies that not only improve clinical events but also reduce symptom burden and physical limitations and improve quality of life. In fact, improving the patient's health status is a key goal of heart failure management, which has been increasingly recognized by practice guidelines (Tsevat, J. et al., J Gen Intern Med. 9:576-582 (1994); Lewis, EF et al., J Heart Lung Transplant 20:1016-1024 (2001)) and is recognized as an important outcome by regulatory agencies. USFDA, "Treatment for Heart Failure: Endpoints for Drug Development Guidance forIndustry[Treatment of Heart Failure: Drug Endpoints Development Guidance for Industry],” https: / / wwwfdagov / regulatory-informatioh / search-fda-guidance-documents / treatment-heart-failure-endpoints-dmg-development-guidance-industry (2019).

[0356] In the DAPA-HF trial discussed in Example 1, the SGLT2 inhibitor dapagliflozin was added to other guideline-recommended therapies in 4,744 HFrEF patients, reducing the risk of mortality and HF hospitalization and improving symptoms. See also McMurray, JJV et al., NEngl J Med, doi: 10.1056 / NEJMoa1911303 [Epub ahead of print] (September 19, 2019); McMurray, JJV et al., Eur J Heart Fail. 21: 665-675 (2019); McMurray JJV et al., Eur J Heart Fail. , doi: 10.1002 / ejhf.1548. [Epub ahead of print] (July 15, 2019), which are incorporated by reference in their entireties. To better understand the effects of dapagliflozin on a broad range of health status outcomes, we examined its effects on various domains of the KCCQ—a validated self-management tool that quantifies heart failure-related symptoms, function, and quality of life.

[0357] method

[0358] The design of the DAPA-HF trial, the baseline characteristics of the study patients, and the primary outcomes are as described in Example 1 and in McMurray, JJV et al., N Engl J Med, doi: 10.1056 / NEJMoa1911303 [Epub ahead of print] (September 19, 2019); McMurray, JJV et al., Eur J Heart Fail. 21: 665-675 (2019); and McMurray JJV et al., Eur J Heart Fail., doi: 10.1002 / ejhf.1548. [Epub ahead of print] (July 15, 2019). The primary clinical outcome of the DAPA-HF trial was the composite of the onset of worsening heart failure (HF hospitalization or urgent HF visit) or cardiovascular (CV) death, whichever occurred first. Other clinical outcomes assessed were the occurrence of HF hospitalization or CV death; worsening HF events (HF hospitalization or urgent HF visit), hospitalization for HF, cardiovascular death, and all-cause death.

[0359] Kansas City Cardiomyopathy Questionnaire

[0360] The KCCQ was completed electronically by patients without the assistance of on-site investigators (validated) and assessed at randomization, 4 months, and 8 months. The KCCQ is a 23-item self-administered disease-specific instrument that quantifies symptoms (frequency, severity, and recent changes), physical function, quality of life, and social functioning over the previous two weeks. In the KCCQ, the total symptom score (TSS) quantifies symptom frequency and severity, the KCCQ clinical summary score (KCCQ-CSS) includes physical function and symptom domains, and the KCCQ total summary score (OSS) is derived from the following domains (total symptom score, physical function, quality of life, and social functioning). For each domain, validity, reproducibility, responsiveness, and interpretability were established separately. Scores were converted to a range of 0-100, where higher scores reflect better health status.

[0361] Statistical analysis

[0362] In this study, patients were divided into three subgroups according to the tertiles of baseline KCCQ-TSS (which was a KCCQ domain pre-specified as a secondary endpoint): (i) ≤65.6, (ii) 65.7-87.5, and (iii) >87.5 points. Baseline characteristics were summarized as means and standard deviations, medians and interquartile ranges, or percentages. Rates of CV death and HF worsening were calculated between KCCQ-TSS tertiles (regardless of treatment assignment) and compared using Kaplan-Meier estimates.

[0363] To compare the effects of dapagliflozin as compared with placebo on clinical outcomes across tertiles of the KCCQ-TSS, we used Kaplan–Meier estimates to assess time-to-event data and Cox proportional-hazards models, stratified according to diabetes status, to calculate hazard ratios, 95% confidence intervals, and two-sided P values ​​using history of HF hospitalization and treatment-group assignment as fixed factors.

[0364] Differences in mean KCCQ-TSS, CSS, and OSS between treatment groups at 4 and 8 months were analyzed for surviving patients using mixed models for repeated measures, and least square mean differences between treatment groups adjusted for baseline values ​​were estimated. A responder analysis was performed examining the proportion of patients who deteriorated and had a clinically important improvement on the KCCQ at 8 months. Established clinically meaningful KCCQ thresholds (≥5 points (at least small), ≥10 points (moderate), and ≥15 points (large) changes) were used for all responder analyses across the KCCQ domains. Multiple imputation was used to account for missing KCCQ values ​​to compare the proportion of responders between patients treated with dapagliflozin and placebo (see below).

[0365] Odds ratios to estimate differences between treatment groups, and their corresponding 95% confidence intervals and two-sided p values, were estimated from logistic regression models that included treatment group, stratification variable (T2D at randomization), and baseline KCCQ value; these models used imputed data to address missing KCCQ values, and imputed values ​​were combined using Rubin's rule. Missing data were imputed using the missing at random assumption and predicted mean-matched multiple imputation models with fully conditional specification implemented in SAS procedure MI (FCS statement). The imputation model included treatment group, type 2 diabetes randomization stratum, KCCQ scores at baseline, 4 months, and 8 months, and a categorical variable representing the number of HF events reported by the investigator in the interval from randomization to 4 months and in the interval from 4 to 8 months (0, 1, ≥2 events). Deaths were handled by assigning the worst grade value. Patients whose baseline KCCQ scores were too high to improve by a certain threshold (e.g., baseline scores ≥95 for a 5-point threshold) were defined as improved if their scores at 8 months were still high (i.e., ≥95). Similarly, patients whose KCCQ scores at baseline were too low to have worsened were defined as worsening if their scores at 8 months remained low. All analyses were performed with the use of STATA, version 15.1 (College Station TX, USA) and SAS, version 9.4 (SAS Institute, Cary, NC, USA). A P value of 0.05 was considered statistically significant.

[0366] result

[0367] Overall, 4744 patients were randomized. Baseline KCCQ TSS was available for 4,443 (93.7%) patients. Median KCCQ TSS was 77.1 (IQR 58.3-91.7). Table 4 shows the number and proportion of patients in tertiles of KCCQ-TSS.

[0368] Table 4

[0369]

[0370]

[0371]

[0372] Patient characteristics

[0373] Compared with participants with higher KCCQ-TSS scores at baseline, participants with lower scores were younger, more often female, white, and enrolled in Europe and America. They also had higher body mass index and natriuretic peptide levels; and lower eGFR (Table 4); were more likely to be in NYHA functional class III / IV rather than class II, and to have type 2 diabetes and atrial fibrillation. Regarding background HF medications, patients with lower baseline KCCQ-TSS were more commonly treated with mineralocorticoid receptor antagonists (MRAs) and diuretics. Baseline use of angiotensin receptor neprilysin inhibitors (ARNIs) was generally lower but similar across age groups. The proportion of patients treated with implantable cardiac devices was generally comparable across KCCQ-TSS subgroups.

[0374] Clinical Results

[0375] Patients with lower baseline KCCQ-TSS had a higher incidence of CV death or worsening HF (25.0%, 17.3%, and 13.6% in KCCQ-TSS tertiles ≤65.6, 65.7-87.5, and >87.5, respectively; P < 0.001). In the Cox proportional hazards model, patients with lower baseline KCCQ-TSS had a higher risk of CV death or worsening HF (tertile >87.5: indicator; tertile 65.7-87.5: HR 1.30 (95% CI: 1.08-1.56), p = 0.006; tertile ≤65.6: HR 1.93 (95% 1.62-2.30), p < 0.001; Figure 5 ).

[0376] The effects of dapagliflozin on the range of clinical outcomes are summarized in Figure 6 Dapagliflozin reduced the primary outcome of CV death or worsening HF across the entire KKCQ-TSS range, with no evidence of heterogeneity in treatment effect (HR (95% CI) from lowest to highest tertile: 0.70 (0.57-0.86), 0.77 (0.61-0.98), and 0.62 (0.46-0.83), respectively; P value for heterogeneity = 0.52). Similar results were observed for CV death or hospitalization for HF; worsening HF events; HF hospitalization; CV death; and all-cause mortality ( Figure 6 ; all P values ​​for heterogeneity were non-significant).

[0377] Poor health status

[0378] The average changes of KCCQ-TSS, CSS and OSS over time were Fig. 7A , 7Band 7C. Patients treated with dapagliflozin had modest but significant improvements in mean KCCQ-TSS, CSS, and OSS at 4 months (1.9, 1.8, and 1.7 points higher than placebo, respectively; all P values ​​< 0.0001). These beneficial effects amplified over time, with corresponding mean differences of 2.8, 2.5, and 2.3 points for dapagliflozin versus placebo at 8 months (all P values ​​< 0.0001).

[0379] The results of the responder analysis are shown in Figures 8A-8F A minority of patients treated with dapagliflozin had clinically significant worsening (KCCQ-TSS decrease of ≥5 points (25.3% vs. 32.9%; OR, 0.84, 95% CI, 0.78-0.90; p<0.0001); more patients treated with dapagliflozin had at least small (58.3% vs. 50.9%), moderate (54.5% vs. 47.6%), and large (54.0% vs. 48.2%) improvements (corresponding odds ratios (OR), 95% CI: 1.15, (1.08-1.23); 1.15 (1.08-1.22); 1.14 (1.07-1.22); number needed to treat (NNT) = 14 (10-23), 1 5 (11-25), and 18 (12-35), respectively; all P values ​​<0.0001; Figures 8A-8B The findings from the KCCQ-CSS and OSS were similar ( Figures 8C-8F ).

[0380] discuss

[0381] In this prospective study, which assessed prespecified assessments of health status using the KCCQ in the DAPA-HF trial, dapagliflozin treatment reduced the risk of all key clinical events (including the primary composite endpoint of CV death or HF worsening, and its components) to a similar extent across the entire KCCQ range at baseline, suggesting that the beneficial effects of dapagliflozin on HF outcomes were independent of impairments in health status at baseline. In addition, dapagliflozin significantly improved the KCCQ-TSS, CSS, and OSS (which collectively include symptoms, physical function, quality of life, and social functioning), and these effects expanded over time. Finally, significantly fewer patients treated with dapagliflozin experienced clinically meaningful worsening, and significantly more patients experienced at least small, moderate, and large clinically meaningful improvements in health status. These effects were substantial after only 8 months of treatment, with a number needed to treat of 12 to 18.

[0382] These results have several important implications. First, analysis of clinical outcomes across baseline KCCQ-TSS subgroups showed no evidence of heterogeneity in the benefit of dapagliflozin by degree of symptomatic impairment at baseline. A previously reported prespecified subgroup analysis of the primary endpoint (CV death or worsening HF) showed that the benefit of dapagliflozin was more pronounced in patients with NYHA class II relative to class III-IV. However, the NYHA class, while prognostically important, represents a more subjective, arbitrary, and non-patient-centered assessment of symptom burden; and given this report, the observation from the previous NYHA class subgroup analysis may have been a chance finding.

[0383] Second, the findings substantially extend previously reported effects of dapagliflozin on health status in patients with HFrEF, as measured by the KCCQ. In the Effect of Dapagliflozin on Biomarkers, Symptoms, and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction (DEFINE-HF) trial, a medium-sized, randomized, placebo-controlled trial conducted at 26 sites in the United States, dapagliflozin was also shown to have favorable effects on multiple domains of the KCCQ - the mean differences between dapagliflozin and placebo were slightly greater than those observed in the DAPA-HF trial, but responder analyses and the number needed to treat were comparable after only 12 weeks of treatment. Nassif, ME et al., Circulation 140:1463-1476 (September 2019). These findings confirm these beneficial effects on symptoms, function, and quality of life in a larger global trial with a longer follow-up period. In summary, results from the DEFINE-HF and DAPA-HF trials showed that dapagliflozin significantly improved heart failure-related health status (as measured by the KCCQ), with benefits occurring early and lasting over the long term.

[0384] Third, in the DAPA-HF trial, the magnitude of KCCQ improvement observed with dapagliflozin compared with placebo was superior to other effective therapies for HFrEF. For example, in the Systolic Heart Failure Treatment Trial (SHIFT) with the If Inhibitor Ivabradine, ivabradine resulted in a mean improvement of 2.4 points on the KCCQ-OSS and 1.8 points on the KCCQ-CSS after 12 months of treatment. Ekman, I. et al., Eur Heart J 32: 2395-2404 (2011). In the PARADIGM-HF trial, Lewis, EF et al., Circ Heart Fail. 10: doi: 10.1161 / CIRCHEARTFAILURE.116.003430 (2017), sacubitril-valsartan showed improvements of 1.3 points and 0.9 points on the KCCQ-OS and KCCQ-CS, respectively, after 8 months of treatment compared with enalapril. In the HF-ACTION trial, KE et al., JAMA [Journal of the American Medical Association] 301: 1451-1459 (2009), exercise therapy in HFrEF improved the KCCQ-OSS by 1.9 points. In the MADIT-CRT trial of cardiac resynchronization therapy (CRT) in patients with HFrEF and prolonged QRS interval, Veazie, PJ et al., JAm Coll Cardiol. [Journal of the American College of Cardiology] 60: 1940-1944 (2012), CRT treatment improved the KCCQ-TSS, CSS, and OSS by 2.0, 2.0, and 2.4 points, respectively, in patients with left bundle branch block (LBBB), while the KCCQ did not significantly improve in patients without LBBB. Despite the small number of responder analyses previously performed, the magnitude of benefit observed with dapagliflozin in the responder analysis of DAPA-HF is also favorable compared to previously observed results. Ekman, I. et al., Eur Heart J 32: 2395-2404 (2011). Of note, the number needed to treat for a clinically meaningful improvement in KCCQ was based on a comparison of dapagliflozin-treated patients with placebo-treated patients (who also had improved health status, consistent with a sizable “placebo effect” seen in our study as well as in the DEFINE-HF trial). Therefore, the magnitude of the effect of dapagliflozin on health status in clinical practice (obviously, without the use of placebo) may be even greater than what we observed. Given the importance of reducing symptom burden and functional limitations and improving quality of life (key goals of HF treatment recognized by practice guidelines and regulatory agencies), our findings provide further support for dapagliflozin as a new treatment option for patients with HFrEF.

[0385] in conclusion

[0386] In the DAPA-HF trial, dapagliflozin treatment reduced death and heart failure hospitalizations across the entire range of baseline KCCQ values ​​and improved symptom burden, functional status, and quality of life in patients with HFrEF. In addition, dapagliflozin significantly increased the proportions of patients experiencing small, moderate, and large improvements in health status; these effects were substantial and clinically important.

[0387] Example 3

[0388] Results of the Phase III DAPA-HF trial: Effects of dapagliflozin on clinical,

[0389] Effects of metabolic, hemodynamic, and renal outcomes

[0390] Introduction

[0391] In the DAPA-HF trial discussed in Example 1, it was demonstrated that SGLT2 inhibition resulted in a similar reduction in the primary outcome of worsening HF events or death from cardiovascular causes in HF patients with and without diabetes. See also McMurray, JJV et al., Eur J Heart Fail [European Journal of Heart Failure] 21: 665-675 (2019); McMurray, JJV et al., N Engl J Med [New England Journal of Medicine] doi: 10.1056 / NEJMoa1911303 [Epub ahead of print] (September 19, 2019), which are incorporated by reference in their entirety. In the prespecified analysis presented in this example, the efficacy and safety of dapagliflozin and metabolic and hemodynamic changes in HF patients across the range of baseline glycated hemoglobin (also called hemoglobin A1c or HbAlc) in DAPA-HF are described.

[0392] method

[0393] Eligibility, baseline characteristics, and exclusion criteria for DAPA-HF study patients are as described in Example 1 and McMurray JJV et al., Eur J Heart Fail., doi: 10.1002 / ejhf.1548. [Epub ahead of print] (July 15, 2019); McMurray, JJV et al., Eur J Heart Fail 21: 665-675 (2019); McMurray, JJV et al., NEngl J Med, doi: 10.1056 / NEJMoa1911303 [Epub ahead of print] (September 19, 2019). The study procedures, results, and statistical analyses were also as described in Example 1 and McMurray, JJV et al., Eur J Heart Fail [European Journal of Heart Failure] 21: 665-675 (2019); McMurray, JJV et al., NEngl J Med [New England Journal of Medicine], doi: 10.1056 / NEJMoa1911303 [Epub ahead of print] (September 19, 2019).

[0394] Baseline classification of diabetes status

[0395] The investigators recorded whether the patients had a history of diabetes at the enrollment visit (Visit 1). Glycated hemoglobin (HbA1c) levels were also measured in a central laboratory at Visit 1 and at the repeat Visit 2 (randomization visit) that occurred 14 (±7) days later. In this prespecified subgroup analysis, patients were classified as having diabetes if they had a history of diabetes or had a glycated hemoglobin of at least 6.5% (≥48mmol / mo1) at Visit 1 and Visit 2. Patients with a glycated hemoglobin level of <5.7 (<39mmol / m1) at Visits 1 and 2 were considered to have normal glycated hemoglobin. For the purposes of this study, patients with a glycated hemoglobin ≥5.7% and <6.5% were considered to have prediabetes. Same as above.

[0396] result

[0397] patient

[0398] Blood sugar status at baseline

[0399] Of the 4,744 patients included, 2,605 (55%) did not have diabetes. Of the remaining patients, 1,983 (41.8%) had a history of diabetes at screening, and an additional 156 (3.3%) had previously undiagnosed diabetes, defined as HbA1c ≥ 6.5% at both visit 1 (enrollment) and visit 2 (randomization). Of the 2,605 patients without diabetes, 1,748 (67.1%) had HbA1c levels ≥ 5.7% at visit 1 or 2, while 839 patients (32.2%) had HbA1c levels < 5.7% at both visits 1 and 2. In addition, 12 patients had only monoglycated HbA measurements < 5.7%, while 6 patients had missing baseline HbA1c measurements (these 18 patients were included in the normal HbA1c group).

[0400] Patient characteristics according to baseline glycemic status

[0401] The baseline characteristics of patients with and without diabetes are shown in Table 5, and there was a good balance between patients assigned to dapagliflozin or placebo in each patient group (Table 6). Patients without diabetes were less likely to be black and less likely to have an ischemic etiology than participants with diabetes (Table 5). Participants without diabetes had lower mean body mass index, heart rate, systolic blood pressure, and NT-proBNP levels compared with those with diabetes. Participants without diabetes had a higher mean eGFR than those with diabetes. The mean glycated hemoglobin level was 5.8% in patients without diabetes and 7.4% in patients with diabetes. The median duration of diabetes was 7.41 years (IQR 2.75.13.5).

[0402] At baseline, patients without diabetes had better NYHA functional class and KCCQ-TSS compared with patients with diabetes.

[0403] Table 5: Patient characteristics according to diabetes status at baseline*

[0404]

[0405]

[0406] T2DM = type 2 diabetes mellitus.

[0407] * Positive and negative values ​​mean ±SD.

[0408] Percentages may not total 100 due to rounding.

[0409] ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, DPP-4 = dipeptidyl peptidase 4, GFR = glomerular filtration rate, GLP-1 = glucagon-like peptide 1, IQR = interquartile range, LVEF = left ventricular ejection fraction, MRA = mineralocorticoid receptor antagonist, NT-proBNP = N-terminal pro-B-type natriuretic peptide, NYHA = New York Heart Association, KCCQ-TSS = Kansas City Cardiomyopathy Questionnaire Total Symptom Score - 0 to 100, with higher scores indicating fewer symptoms and physical limitations related to heart failure.

[0410] Race was reported by the investigators.

[0411] §BMI is weight in kilograms divided by height in meters squared.

[0412] A total of 993 patients (41.8%) in the dapagliflozin group and 990 (41.8%) in the placebo group had a history of diabetes at baseline. An additional 82 patients in the dapagliflozin group and 74 in the placebo group had not been previously diagnosed with diabetes, defined as a glycated hemoglobin level of 6.5% or higher (≥48 mmol / mol) measured in a central laboratory at screening and randomization.

[0413] Implantable cardioverter-defibrillator or cardiac resynchronization therapy with a defibrillator.

[0414] **Cardiac resynchronization therapy with or without defibrillator.

[0415] Table 6: Baseline characteristics and study medication assignment according to diabetes status

[0416] No diabetes (n=2605)

[0417]

[0418]

[0419] Diabetes (n=2139)

[0420]

[0421]

[0422] * Positive and negative values ​​mean ±SD.

[0423] Percentages may not total 100 due to rounding.

[0424] ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, DPP-4 = dipeptidyl peptidase 4, GFR = glomerular filtration rate, GLP-1 = glucagon-like peptide 1, IQR = interquartile range, LVEF = left ventricular ejection fraction, MRA = mineralocorticoid receptor antagonist, NT-proBNP = N-terminal pro-B-type natriuretic peptide, NYHA = New York Heart Association, KCCQ-TSS = Kansas City Cardiomyopathy Questionnaire Total Symptom Score - 0 to 100, with higher scores indicating fewer symptoms and physical limitations related to heart failure.

[0425] Ethnicity was reported by the investigators.

[0426] §BMI is weight in kilograms divided by height in meters squared.

[0427] A total of 993 patients (41.8%) in the dapagliflozin group and 990 (41.8%) in the placebo group had a history of diabetes at baseline. An additional 82 patients in the dapagliflozin group and 74 in the placebo group had not been previously diagnosed with diabetes, defined as a glycated hemoglobin level of 6.5% or higher (≥48 mmol / mol) measured in a central laboratory at screening and randomization.

[0428] Implantable cardioverter-defibrillator or cardiac resynchronization therapy with a defibrillator.

[0429] **Cardiac resynchronization therapy with or without defibrillator.

[0430] result

[0431] Results according to baseline glycemic status

[0432] Patients without diabetes had lower rates of pre-specified mortality and worse HF outcomes (Table 7, Figures 9A-9D and Fig. 10A Among participants without diabetes, the incidence of the primary endpoint was highest in participants in the top third of baseline HbA1c (≥6.0%), i.e., individuals with prediabetes ( Fig. 10A The risk of the renal composite endpoint was also lower among participants without diabetes ( Fig.14 ). In contrast, the overall change from baseline in the KCCQ-TSS did not differ between participants with or without diabetes.

[0433]

[0434]

[0435] Effects of dapagliflozin relative to placebo according to baseline glycemic status

[0436] Table 7 and Fig. 10B The effects of dapagliflozin on the primary composite outcome and on each of the individual outcomes of mortality and hospital admission and urgent visits for worsening heart failure requiring intravenous therapy are shown. The effects of dapagliflozin on each outcome were similar in patients with and without diabetes, and the effects of the study drug on the renal composite outcome were also similar.

[0437] Among patients without diabetes at baseline, the effect of dapagliflozin on the primary outcome was consistent across the range of HbA1c when divided into three equal groups ( Fig. 10A Specifically, for patients in the bottom third (HbA1c level ≤5.6%), the hazard ratio for dapagliflozin relative to placebo was 0.74 (95% C1 0.53, 1.04), compared with 0.71 (0.48, 1.04) for the middle third (>5.6-<6.0%) and 0.72 (0.52, 1.00) for the top third (≥6.0%); Pinteraction = 0.837. Additional analyses using HbA1c as a continuous variable showed a benefit of dapagliflozin across the entire range included ( Figures 12A-12D ).

[0438] Between baseline and 8 months, dapagliflozin increased KCCQ-TSS by 2.2 (95% CI 10.7-3.7) points in patients without diabetes and by 3.5 (95% CI 1.6-5.4) points in patients with diabetes compared with placebo; Pinteraction = 0.176 (Table 7).

[0439] Among individuals without diabetes, more patients in the dapagliflozin group self-reported an increase of at least 5 points (minimally important difference) in the KCCQ-TSS compared with the placebo group (57.7% vs. 51.7%; odds ratio 1.12 (95% CI 1.03, 1.22) and fewer patients reported a significant worsening (26.0% vs. 31.3%; odds ratio 0.88 (0.81, 0.97); P<0.01 for both comparisons. The corresponding proportions among individuals with diabetes were: ≥5-point improvement - 58.9% vs. 49.9%, odds ratio 1.20 (1.09, 1.31); worsening, 24.5% vs. 34.8%, odds ratio 0.78 (0.71, 0.87); P<0.001 for both comparisons (P interaction for improvement = 0.294 and P interaction for worsening = 0.075).

[0440] Among individuals without diabetes, 157 developed T2D during the trial, of whom 150 (95.5%) had prediabetes (A1c 5.7-6.4%) (136 [86.6%] used the more stringent 6.0-6.4% criteria). Compared with those who remained free of diabetes, those who developed T2D had higher mean baseline A1c (6.2±0.3 vs 5.7±0.4%; p<0.001), greater BMI (28.5±5.9 vs 27.1±5.7 kg / m 2 ; p = 0.003), and lower eGFR (61.5 ± 17.4 vs. 68.2 ± 19.3 ml / min / 1.73 m 2 ; p<0.001). Dapagliflozin reduced new-onset diabetes by 32%: placebo 93 / 1307 (7.1%) vs. dapagliflozin 64 / 1298 (4.9%); HR 0.68 (95% CI, 0.50-0.94; p=0.019) (Cox.)( Fig.17 ).

[0441] Laboratory measurements, weight, and blood pressure

[0442] Figures 11A-11E Changes in laboratory measurements, weight, and blood pressure adjusted for baseline values ​​are shown. Glycated hemoglobin changed little in patients without diabetes, but decreased modestly in patients with diabetes at 60 days (Pinteraction<0.0001)( Fig.11A The body weight and systolic blood pressure of both groups decreased (respectively Fig. 11B and 11C ). Hematocrit increased after dapagliflozin treatment in both groups and plateaued after approximately 4 months; the increase was less in patients without diabetes compared with those with diabetes (Pinteraction = 0.0002) ( Fig.11D The initial increase in creatinine with dapagliflozin treatment was small in both groups, although the difference between treatments was attenuated at 6 months; patients without diabetes had a smaller increase compared with those with diabetes (P interaction = 0.0005) ( Fig.11E ).

[0443] N-terminal pro-B-type natriuretic peptide

[0444] In patients without diabetes, NT-proBNP decreased by 144±2286 pg / ml in the dapagliflozin group and increased by 84±2993 pg / ml in the placebo group between baseline and 8 months; between-treatment difference -278 (-485 to -71) pg / ml; p=0.009. The corresponding changes in participants with diabetes were a decrease of 257±2502 pg / ml in the dapagliflozin group and an increase of 121±2884 pg / ml in the placebo group; between-treatment difference -333 (-562 to -104) pg / ml; p=0.004 (Pinteraction=0.728).

[0445] Tolerability and safety

[0446] Among patients without diabetes, 144 patients (11.1%) in the dapagliflozin group and 141 patients (10.8%) in the placebo group discontinued study drug treatment. Among patients with diabetes, these numbers were 105 (9.8%) and 117 (11.0%), respectively.

[0447] The most common adverse events of interest were those related to volume depletion and renal impairment, which were less common in patients without diabetes compared with participants with diabetes (Table 8). The incidence of these adverse events did not differ between dapagliflozin and placebo in either patient group.

[0448]

[0449] T2DM = type 2 diabetes mellitus.

[0450] NA indicates not applicable, as P values ​​were not reported for outcomes with 10 or fewer events.

[0451] *Safety population includes patients who received at least one dose of study drug: dapagliflozin n = 2368 and placebo n = 2368. Numbers reported are patients.

[0452] Severe hypoglycemia was defined as hypoglycemia requiring assistance from another person to actively administer carbohydrates, glucagon, or other corrective measures.

[0453] Serum creatinine doubled in 22 patients without diabetes (1.7%) assigned to dapagliflozin and in 36 patients (2.8%) assigned to placebo, P = 0.08; the corresponding numbers among participants with diabetes were 21 (2.0%) and 41 (3.9%), respectively, P = 0.01.

[0454] In this trial, three patients (0.06%) developed definite or probable diabetic ketoacidosis, all of whom were diabetic patients randomized to dapagliflozin. Severe hypoglycemia occurred in eight patients (0.17%) in this trial, and all eight had diabetes: four randomized to dapagliflozin and four to placebo. Overall, 25 patients (0.53%) had amputations, one in the dapagliflozin group and three in the placebo group among individuals without diabetes, and 12 in the dapagliflozin group and nine in the placebo group among patients with diabetes.

[0455] discuss

[0456] The key finding of this analysis of patients with HF and reduced ejection fraction was that the SGLT2 inhibitor dapagliflozin improved all prespecified mortality and hospitalization outcomes to a similar extent in patients with and without diabetes. Furthermore, in individuals without diabetes, the reduction in the primary outcome with dapagliflozin was consistent across the range of HbA1c levels at baseline, whether assessed as a categorical or continuous measure. Indeed, by chance, the tertile analysis performed in participants without diabetes selected quantiles that reflected the American (≥5.6%) and European (≥6.0%) definitions of prediabetes based on HbA1c criteria. (American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019, Diabetes Care 42(Suppl 1):S13-S28 (2019); Chatterton, H. et al., BMJ 345:e4624 (2012)). The benefits of dapagliflozin were similar in patients with prediabetes (diagnosed using either definition) and those with normal glycated hemoglobin. The data provide compelling evidence that the benefits of SGLT2 inhibition are not limited to patients with diabetes or prediabetes, but also apply to patients with heart failure and reduced ejection fraction, regardless of glycemic status. In addition, the observed benefits were obtained in participants who were already receiving recommended HF therapies, including renin-angiotensin system blockers, beta blockers, and mineralocorticoid receptor antagonists.

[0457] The present analysis also demonstrated the effects of dapagliflozin on metabolic, hemodynamic, and anthropometric measures in people with and without diabetes. As expected, dapagliflozin reduced glycated hemoglobin in patients with type 2 diabetes but had no effect on this measure in patients without diabetes. However, the effects of dapagliflozin on weight, blood pressure, hematocrit, creatinine, and NT-proBNP were similar in direction in patients with and without diabetes, although slightly more pronounced in the former group.

[0458] It can be inferred from the findings of this trial that the benefits of dapagliflozin are independent of lowering plasma glucose. Other mechanisms of action of SGLT2 inhibitors have been proposed, including a diuretic effect. (Hallow, KM et al., Diabetes Obes Metab [Diabetes Obes Metab] 20: 479-487 (2018); McMurray, J., J Diabetes Complications [Journal of Diabetes and Its Complications] 30: 3-4 (2016)). Although this mechanism was not directly measured in this trial, the early reduction in systolic blood pressure and body weight and the increase in creatinine are consistent with a diuretic effect. However, little is known about the effects of SGLT2 inhibitors on urinary sodium and water excretion when added to conventional diuretic therapy, especially in patients with HF, especially in patients without diabetes. (Hallow, KM et al., supra; Devineni, D. et al., Clin Ther 36:698-710 (2014); Nassif, ME et al., Circulation (September 2019); Kosiborod, M. et al., J Diabetes Complications 31:1215-1221 (2017)). There are other possible explanations for the increase in creatinine and hematocrit. SGLT2 inhibitors are thought to cause tubuloglomerular feedback independent of the diuretic effect, which promotes constriction of the afferent glomerular arterioles and a decrease in glomerular filtration rate. (Heerspink, HK, et al., Circulation 134:752-72 (2016); Kidokoro, K., et al., Circulation 140:303-315 (2019). Similarly, the increase in hematocrit may be due to increased renal erythropoietin secretion caused by the improvement in renal function mediated by SGLT2 inhibitors. (Yanai, H., et al., J Clin Med Res 9:178-179 (2017)). The time course of the changes in creatinine and hematocrit we observed was very different, with the initial increase in creatinine reversing after 14 days, while hematocrit gradually increased during the first 4 months and stabilized thereafter. Volume contraction caused by diuresis is unlikely to explain this differential change.

[0459] Other effects independent of diuresis have also been proposed, including effects on ion transporters, fibrosis, adipokines, sympathetic nervous system activity, and vascular function, although clinical evidence to support these effects is sparse (Thomas, MC et al., Diabetologia [Diabetes] 61:2098-2107 (2018); Garg, V et al., Prog Cardiovasc Dis [Progressive Cardiovascular Disease] pii:S0033-0620(19)30102-1 (2019); Wojcik, C. et al., Curr Cardiol Rep [Current Cardiology Reports] 21:130 (2019); Verma et al., Cardiol Rep 21:143 (2019); S. et al., Diabetologia [Diabetes] 61: 2108-2117 (2018). Some data suggest that SGLT2 inhibitors may reduce left ventricular mass, and the effects on cardiac remodeling may explain the reduction in NT-proBNP observed with dapagliflozin. (Verma, S. et al., Circulation [Circulation] (August 22, 2019)). Recent experimental studies have also shown the benefits of SGLT2 inhibitors on cardiac structure and function in animals without diabetes (Thomas, MC et al., Diabetologia [Diabetes] 61: 2098-2107 (2018); Yurista, SR et al., Eur J Heart Fail [European Journal of Heart Failure] 21: 862-873 (2019); Garg, V. et al., Prog Cardiovasc Dis[Progress Cardiovasc Dis] pii: S0033-0620(19)30102-1(2019)). Preventing the decline in renal function may also benefit heart failure.

[0460] In the case of heart failure (those associated with volume depletion), the overall incidence of other adverse events of interest was low and similar in participants with and without diabetes. This finding is also consistent with the view that the diuretic effect is unlikely to be a key mechanism of the beneficial effect of dapagliflozin. Other pre-specified safety outcomes were uncommon in both groups of patients, and discontinuation of study drug was rare in both groups. Severe hypoglycemia and diabetic ketoacidosis did not occur in any patient without diabetes. Although no significant effect on our pre-specified renal outcomes was shown, this occurred in a small number of patients. However, it was found that doubling of serum creatinine was significantly less common in patients receiving dapagliflozin, regardless of whether they had diabetes or not. Serious renal adverse events were also less common in patients assigned to dapagliflozin compared with placebo.

[0461] In conclusion, in patients with HF and reduced ejection fraction, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure and death from cardiovascular causes and improved symptoms, independent of baseline diabetes status and independent of glycated hemoglobin level. These benefits were observed on top of excellent standard of care in persons with and without diabetes. Taken together, these data support the use of dapagliflozin as a treatment for heart failure with reduced ejection fraction in persons with and without diabetes, regardless of their glycemic status.

[0462] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0463] Unless otherwise noted herein, the enumeration of numerical ranges herein is intended only to be used as a shorthand method for referring to each individual value falling within the range, and each individual value is incorporated into the specification as if it were individually narrated herein. All methods described herein can be performed in any suitable order, unless otherwise indicated herein or clearly contradictory to the context. The use of any and all examples or exemplary language (e.g., "such as") provided herein is intended only to better illustrate the present disclosure, without limiting the scope of the present disclosure, unless otherwise required. The language in the specification should not be interpreted as indicating that any unclaimed element is necessary for practicing the present disclosure.

[0464] Various embodiments of the present disclosure are described herein, including the best mode known to the inventor for implementing the present disclosure. After reading the foregoing description, variations of those embodiments will become apparent to those of ordinary skill in the art. The inventors expect that skilled technicians will appropriately adopt such variations, and the inventors intend to practice the present disclosure in a manner different from that specifically described herein. Therefore, the present disclosure includes all modifications and equivalents of the subject matter recited in the appended claims as allowed by applicable law. In addition, unless otherwise indicated herein or clearly contradictory to the context, the present disclosure covers any combination of the above-mentioned elements in all possible variations thereof.

[0465] Example 4

[0466] Results of the DAPA-HF Phase III clinical trial: Effect of dapagliflozin on reducing hyperkalemia in HF patients

[0467] Introduction

[0468] Hyperkalemia often limits the use of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure and reduced ejection fraction (HFrEF), precluding life-saving therapy in these patients. In the prespecified analysis presented in this example, the efficacy of the sodium-glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin was evaluated to determine whether dapagliflozin treatment reduces the risk of hyperkalemia associated with MRA use in patients with HFrEF.

[0469] method

[0470] In the dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial, the risk of developing mild hyperkalemia (potassium >5.5 mmol / L) and moderate / severe hyperkalemia (>6.0 mmol / L) was examined according to background MRA use and randomized treatment assignment by using Cox regression analysis.

[0471] result

[0472] Overall, 3370 (70.1%) DAPA-HF patients were treated with MRAs. Mild hyperkalemia and moderate / severe hyperkalemia occurred in 180 (11%) and 21 (1.2%) patients treated with dapagliflozin, respectively, compared with 204 (12.6%) and 40 (2.4%) patients receiving placebo (Tables 8 and Figures 18A-18B Comparing dapagliflozin with placebo, the hazard ratio (HR) for mild hyperkalemia was 0.86 (0.70-1.05) and for moderate / severe hyperkalemia was 0.50 (0.29, 0.85). Dapagliflozin treatment halved the incidence of moderate / severe hyperkalemia associated with MRA use in patients with HFrEF.

[0473] Table 9: Incidence of Hyperkalemia in DAPA-HF

[0474]

[0475] *Models were adjusted for baseline potassium and stratified by diabetes status at randomization.*

[0476] Excluding baseline K + Those with >5.5 (n=145) **excluding baseline K + Those patients with >6.0 (n=25)

[0477] The following is the implementation scheme of the parent case of this application, which is incorporated into this application.

[0478] 1. A method of treating heart failure with reduced ejection fraction (HFrEF) in a patient, the method comprising administering to the patient an effective amount of a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

[0479] 2. A method of treating HFrEF in a patient who does not have type 2 diabetes (T2D), the method comprising administering to the patient an effective amount of a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

[0480] 3. A method for treating HFrEF in a patient with T2D, the method comprising administering to the patient an effective amount of a SGLT2 inhibitor.

[0481] 4. A method for preventing or delaying fatal cardiovascular events in a patient with HFrEF and without T2D, the method comprising administering to the patient an effective amount of an SGLT2 inhibitor.

[0482] 5. A method for preventing or delaying fatal cardiovascular events in a patient with HFrEF and T2D, the method comprising administering to the patient an effective amount of an SGLT2 inhibitor.

[0483] 6. A method for treating HFrEF in a patient who does not have T2D, the method comprising administering to the patient an effective amount of an SGLT2 inhibitor, wherein the patient does not experience adverse events related to renal dysfunction during the treatment period.

[0484] 7. A method for treating HFrEF in a patient with T2D, the method comprising administering to the patient an effective amount of an SGLT2 inhibitor, wherein the patient does not experience adverse events related to renal dysfunction during the treatment period.

[0485] 8. The method of embodiments 6-7, wherein the absence of adverse events related to renal dysfunction includes no or minimal decrease in eGFR levels, no end-stage renal disease (ESRD) and / or no death due to renal disease.

[0486] 9. A method of reducing the total number of standard heart failure (HF) care agents taken by a patient with HFrEF and without T2D, the method comprising administering to the patient an effective amount of a SGLT2 inhibitor.

[0487] 10. A method of reducing the total number of standard HF care agents taken by a patient with HFrEF and T2D, the method comprising administering to the patient an effective amount of a SGLT2 inhibitor.

[0488] 11. The method of any one of embodiments 1-10, wherein the SGLT2 inhibitor is dapagliflozin, canagliflozin, empagliflozin, sopagliflozin, iplagliflozin or erpagliflozin, or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0489] 12. The method according to embodiment 11, wherein the SGLT2 inhibitor is dapagliflozin, or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0490] 13. The method according to embodiment 12, wherein dapagliflozin is in a non-crystalline solid form.

[0491] 14. The method of embodiment 12, wherein dapagliflozin is in crystalline solid form.

[0492] 15. The method of any one of embodiments 12-14, wherein the dapagliflozin is in the form of a (S)-propylene glycol ((S)-PG) solvate having the following structure:

[0493]

[0494] 16. The method of any one of embodiments 1-15, further comprising administering at least one additional therapeutic agent to the patient.

[0495] 17. A method as described in embodiment 16, wherein the other therapeutic agent is administered in the same or different pharmaceutical composition and at the same or different time as the SGLT2 inhibitor.

[0496] 18. The method of embodiments 16-17, wherein the other therapeutic agent is an anti-diabetic agent, an anti-obesity agent, an anti-hyperlipidemic agent, an anti-atherosclerotic agent, an anti-hypertensive agent, an anti-platelet agent, an anti-thrombotic agent, or an anticoagulant agent.

[0497] 19. The method of embodiment 18, wherein the other therapeutic agent is an anti-diabetic agent.

[0498] 20. The method of embodiment 19, wherein the antidiabetic agent is a biguanide and / or a DPP4 inhibitor.

[0499] 21. The method of embodiment 20, wherein the biguanide is metformin or a pharmaceutically acceptable salt thereof.

[0500] 22. The method of embodiment 20, wherein the DPP4 inhibitor is saxagliptin, linagliptin, or sitagliptin or a pharmaceutically acceptable salt thereof.

[0501] 23. The method of any one of embodiments 1-22, wherein the patient's left ventricular ejection fraction (LVEF) is less than or equal to 40%.

[0502] 24. The method of embodiment 23, wherein the LVEF is less than or equal to 35%, 30% or 25%.

[0503] 25. The method of embodiment 24, wherein the LVEF is at least 20%.

[0504] 26. The method of any one of embodiments 23-25, wherein the LVEF is determined using echocardiography, radionuclide ventriculography, contrast angiography, or cardiac MRI.

[0505] 27. The method of any one of embodiments 12-26, wherein dapagliflozin is orally administered to the patient at a dose of 2.5 mg, 5.0 mg, or 10 mg once a day.

[0506] 28. The method of embodiment 27, wherein the dose of dapagliflozin is 10 mg.

[0507] 29. The method of any one of embodiments 1-28, wherein administering the SGLT2 inhibitor to the patient results in at least one of the following outcomes:

[0508] (i) prolonging the time to first heart failure (HF) event and / or fatal cardiovascular event; and / or

[0509] (ii) reduce the severity of heart failure symptoms; and / or

[0510] (iii) reducing the number of heart failure events and / or reducing the incidence of fatal cardiovascular events.

[0511] 30. The method of embodiment 29, wherein administration of the SGLT2 inhibitor prolongs the time to first heart failure (HF) event.

[0512] 31. The method of embodiment 30, wherein the HF event is a hospitalization for HF or an emergency HF medical visit.

[0513] 32. The method of embodiment 31, wherein the hospitalization for HF comprises an admission lasting at least 24 hours with a primary diagnosis of HF.

[0514] 33. A method as described in any of embodiments 1-32, wherein administration of the SGLT2 inhibitor reduces the total number of hospitalizations due to HF.

[0515] 34. The method of embodiment 33, wherein the total number of hospitalizations for HF includes first and / or recurrent hospitalizations.

[0516] 35. The method of any one of embodiments 32-34, wherein the hospitalization for HF is due to one or more of the following criteria:

[0517] (i) The patient develops new or worsening symptoms of HF; and / or

[0518] (ii) objective evidence of new or worsening HF symptoms; and / or

[0519] (iii) Initiate or intensify HF-specific treatment.

[0520] 36. The method of embodiment 35, wherein the patient's new or worsening symptoms of HF include dyspnea, decreased exercise tolerance, fatigue, and / or worsening end-organ perfusion or other symptoms of volume overload.

[0521] 37. The method of embodiments 35-36, wherein objective evidence of new or worsening symptoms of HF comprises physical examination findings believed to be attributable to HF and / or laboratory evidence of new or worsening HF.

[0522] 38. The method of embodiment 37, wherein the physical examination findings include at least two of the following findings: peripheral edema, increased abdominal distention or ascites, pulmonary rales / crackles / crackles, increased jugular venous pressure and / or hepatojugular venous return, S3 gallop, and / or clinically significant or rapid weight gain associated with fluid retention.

[0523] 39. The method of embodiment 37, wherein the laboratory evidence of new or worsening HF includes at least one of the following findings: an increase in B-type natriuretic peptide (BNP) / N-terminal proBNP (NT-proBNP) concentration consistent with decompensation of heart failure; radiologic evidence of pulmonary congestion; non-invasive diagnostic evidence of clinically significant elevated left or right ventricular filling pressures or low cardiac output or invasive diagnostic evidence in the setting of right heart catheterization.

[0524] 40. The method of embodiments 35-39, wherein the initiation or intensification of treatment specific for HF comprises at least one of: augmentation of oral diuretic therapy, intravenous administration of a diuretic or vasoactive agent, or mechanical or surgical intervention.

[0525] 41. The method of embodiment 40, wherein the mechanical or surgical intervention comprises mechanical circulatory support or mechanical fluid removal.

[0526] 42. The method of embodiment 31, wherein the urgent HF medical visit is an emergency room visit for a primary diagnosis of HF but does not require hospitalization.

[0527] 43. The method of embodiment 31, wherein the emergency HF medical visit is an unplanned emergency visit to a physician's office for a primary diagnosis of HF.

[0528] 44. The method of any one of embodiments 42-43, wherein the patient develops symptoms of HF, and / or has physical examination findings and / or laboratory findings of new or worsening HF.

[0529] 45. The method of embodiment 44, wherein the patient experiences one or more symptoms of HF selected from the group consisting of dyspnea, decreased exercise tolerance, fatigue, and / or worsening end-organ perfusion or other symptoms of volume overload.

[0530] 46. ​​The method of any one of embodiments 42-45, wherein the patient initiates or intensifies treatment specifically for HF.

[0531] 47. The method of any one of embodiments 42-46, wherein the emergency HF medical visit requires intravenous treatment.

[0532] 48. A method as described in any of embodiments 29-47, wherein administration of the SGLT2 inhibitor prolongs the time to a fatal cardiovascular event.

[0533] 49. A method as described in any of embodiments 29-48, wherein the time to the first heart failure event and / or fatal cardiovascular event is delayed by 8 weeks to 2 years from the first administration of the SGLT2 inhibitor.

[0534] 50. A method as described in embodiment 49, wherein the time to the first heart failure event is delayed by 8 weeks to 2 years from the first administration of the SGLT2 inhibitor.

[0535] 51. A method as described in embodiment 49, wherein the time to a fatal cardiovascular event is delayed by 8 weeks to 2 years from the first administration of the SGLT2 inhibitor.

[0536] 52. The method of embodiment 29, wherein administration of the SGLT2 inhibitor reduces worsening of HF symptoms in the treated patient.

[0537] 53. A method as described in embodiment 52, wherein the patient's reduction in worsening heart failure symptoms lasts for 12-36 months.

[0538] 54. A method as described in embodiments 52-53, wherein the reduction in worsening of heart failure symptoms is characterized by a reduction in the number of hospitalizations for HF by the patient.

[0539] 55. The method of any one of embodiments 52-54, wherein the reduction in worsening of heart failure symptoms is characterized by a reduction in the number of emergency HF medical visits by the patient.

[0540] 56. The method of embodiment 55, wherein the emergency HF medical visit is an emergency room visit or an urgent outpatient medical office visit.

[0541] 57. A method as described in any of embodiments 52-56, wherein the reduction in worsening of heart failure symptoms is characterized by the patient having a higher score on the Kansas City Cardiomyopathy Questionnaire (KCCQ) compared to the patient's score before administration of the SGLT2 inhibitor.

[0542] 58. The method of embodiment 57, wherein the higher score on the KCCQ occurs within 8 months from the start of SGLT2 inhibitor administration.

[0543] 59. A method as described in embodiments 57-58, wherein the higher score on the KCCQ is at least 5 points higher than the score before administration of the SGLT2 inhibitor.

[0544] 60. The method of embodiments 57-58, wherein the higher score on the KCCQ is at least 10 points higher than the score before administration of the SGLT2 inhibitor.

[0545] 61. The method of embodiments 57-58, wherein the higher score on the KCCQ is at least 15 points higher than the score before administration of the SGLT2 inhibitor.

[0546] 62. The method of embodiments 57-61, wherein the KCCQ score is the KCCQ-Total Symptom Score (TSS).

[0547] 63. A method as described in embodiment 62, wherein the higher score on the KCCQ-TSS is achieved regardless of the patient's threshold KCCQ-TSS score before administration of the SGLT2 inhibitor.

[0548] 64. The method of embodiments 57-61, wherein the KCCQ score is the KCCQ-Clinical Symptom Score (CSS).

[0549] 65. The method of embodiments 57-61, wherein the KCCQ score is a KCCQ-Summary Summary Score (OSS).

[0550] 66. A method as described in embodiment 29, wherein the administration of the SGLT2 inhibitor reduces the number of HF events and / or reduces the incidence of fatal cardiovascular events.

[0551] 67. A method as described in embodiment 66, wherein administration of the SGLT2 inhibitor reduces the number of HF events.

[0552] 68. The method of embodiment 67, wherein the HF event is a hospitalization for HF or an emergency HF medical visit.

[0553] 69. A method as described in embodiment 68, wherein administration of the SGLT2 inhibitor reduces the number of hospitalizations due to HF.

[0554] 70. The method of embodiment 68, wherein administration of the SGLT2 inhibitor reduces the number of urgent HF medical visits.

[0555] 71. The method of embodiment 70, wherein the urgent HF medical visit is an emergency room visit.

[0556] 72. The method of embodiments 70-71, wherein the emergency HF medical visit requires intravenous treatment.

[0557] 73. A method as described in embodiment 66, wherein administration of the SGLT2 inhibitor reduces the incidence of fatal cardiovascular events.

[0558] 74. The method of any one of embodiments 66-73, wherein administration of the SGLT2 inhibitor reduces the composite of hospitalization for HF or a fatal cardiovascular event.

[0559] 75. The method of any one of embodiments 1-74, wherein the patient is receiving one or more standard HF care agents to treat HF ​​prior to or during administration of the SGLT2 inhibitor.

[0560] 76. The method of embodiment 75, wherein the one or more standard HF care agents are selected from the group consisting of angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers, mineralocorticoid receptor antagonists (MRAs), neprilysin inhibitors, and diuretics.

[0561] 77. The method of embodiments 75-76, wherein at least one of the standard HF care agents is a therapeutically effective amount of an angiotensin converting enzyme (ACE) inhibitor.

[0562] 78. The method of any one of embodiments 75-77, wherein at least one of the standard HF care agents is a therapeutically effective amount of angiotensin II receptor blocker (ARB).

[0563] 79. The method of any one of embodiments 75-78, wherein at least one of the standard HF care agents is a beta blocker.

[0564] 80. The method of any one of embodiments 75-79, wherein at least one of the standard HF care agents is a mineralocorticoid receptor antagonist (MRA).

[0565] 81. The method of any one of embodiments 75-80, wherein at least one of the standard HF care agents is a neprilysin inhibitor.

[0566] 82. The method of any one of embodiments 75-81, wherein at least one of the standard HF care agents is a loop diuretic.

[0567] 83. The method of any one of embodiments 1-82, wherein the patient to whom the SGLT2 inhibitor is administered has a New York Heart Association (NYHA) heart failure classification of II to IV.

[0568] 84. The method of any one of embodiments 1-83, wherein the patient has NYHA heart failure classification II.

[0569] 85. The method of any one of embodiments 1-83, wherein the patient's NYHA heart failure classification is III or IV.

[0570] 86. The method of any one of embodiments 1-85, wherein the patient has an eGFR of ≥30 ml / min / 1.73 m2 prior to administration of the SGLT2 inhibitor.

[0571] 87. The method of any one of embodiments 1-86, wherein the patient maintains ≥30 ml / min / 1.73 m during administration of the SGLT2 inhibitor. 2 eGFR.

[0572] 88. A method as described in any of embodiments 1-87, wherein the patient has a plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) level of at least 400 pg / ml, at least 600 pg / ml, or at least 900 pg / ml prior to administration of the SGLT2 inhibitor.

[0573] 89. The method of any one of embodiments 1-88, wherein the patient has been medically diagnosed with symptomatic HFrEF prior to administration of the SGLT2 inhibitor.

[0574] 90. The method of embodiment 89, wherein the patient has been diagnosed with HFrEF for at least two months prior to administration of the SGLT2 inhibitor.

[0575] 91. A method as described in any of embodiments 1-90, wherein the patient suffers from atrial fibrillation and / or atrial flutter prior to administration of the SGLT2 inhibitor.

[0576] 92. A method as described in any of embodiments 1-90, wherein the patient does not suffer from atrial fibrillation or atrial flutter prior to administration of the SGLT2 inhibitor.

[0577] 93. The method of any one of embodiments 1-92, wherein administration of the SGLT2 inhibitor lowers the patient's HbA1c.

[0578] 94. A method as described in any of embodiments 1-93, wherein the SGLT2 inhibitor is administered to reduce the patient's systolic blood pressure.

[0579] 95. A method as described in any of embodiments 1-94, wherein the SGLT2 inhibitor is administered to reduce the patient's body weight.

[0580] 96. A method as described in any one of embodiments 1-95, wherein administration of the SGLT2 inhibitor reduces the patient's NT-proBNP level.

[0581] 97. The method of any one of embodiments 94-96, wherein the reduction occurs within 8 months from the start of administration of the SGLT2 inhibitor.

[0582] 98. The method of any one of embodiments 84-96, wherein administration of the SGLT2 inhibitor results in improvement in NYHA HF classification.

[0583] 99. The method of any one of embodiments 1-98, wherein administration of the SGLT2 inhibitor results in a reduction in recurrent hospitalizations for HF or a reduction in recurrent HF events.

[0584] 100. The method of embodiment 99, wherein recurrent HF events comprise hospitalization for HF or emergency HF medical visits.

[0585] 101. The method of any one of embodiments 1-100, wherein administration of the SGLT2 inhibitor results in a lower incidence of death due to non-cardiovascular causes.

[0586] 102. A method for reducing the incidence of a primary composite endpoint of cardiovascular death, HF hospitalization, or urgent HF medical visit in HFrEF patients treated with an SGLT2 inhibitor and standard HF care agents, wherein the incidence is reduced relative to patients treated with standard HF care agents alone.

[0587] 103. A method for reducing the incidence of a secondary composite endpoint of cardiovascular death or HF hospitalization in HFrEF patients treated with an SGLT2 inhibitor and standard HF care medications, wherein the incidence is reduced relative to patients treated with standard HF care agents alone.

[0588] 104. The method of embodiments 102-103, wherein the SGLT2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt, solvate, mixed solvate, complex or prodrug thereof.

[0589] 105. The method of embodiment 104, wherein the dapagliflozin is administered at 10 mg once daily.

[0590] 106. A method for reducing the incidence of all-cause mortality in HFrEF patients treated with an SGLT2 inhibitor.

[0591] 107. The method of embodiment 106, wherein the all-cause mortality includes death due to cardiovascular causes and non-cardiovascular causes.

Claims

1. The use of dapagliflozin for the preparation of a medicament for reducing the incidence of cardiovascular death and worsening of heart failure in patients with reduced ejection fraction, wherein the patient does not suffer from type II diabetes; wherein the patient is also administered at least one standard heart failure care agent; and wherein the incidence of cardiovascular death and worsening of heart failure was reduced compared to a regimen in which patients received at least one standard heart failure care agent alone; The use further improves symptoms of heart failure; Worsening heart failure included multiple unplanned hospitalizations for heart failure and / or multiple emergency heart failure visits.

2. The use according to claim 1, wherein the multiple unplanned hospitalizations for heart failure are due to one or more of the following: a) The patient develops new or worsening symptoms of heart failure; and / or b) objective evidence of new or worsening symptoms of heart failure; and / or c) Initiate or intensify treatment specifically for heart failure.

3. The use according to claim 1, wherein the multiple unplanned hospitalizations for heart failure comprise recurrent hospitalizations for heart failure.

4. The use according to claim 1, wherein the multiple emergency heart failure visits include one or more of the following: a) Emergency room visit for a primary diagnosis of heart failure, but not requiring hospitalization; b) emergency room visit for a primary diagnosis of heart failure, initiation or intensification of treatment other than augmentation of oral diuretic therapy alone, but not requiring hospitalization; c) an unplanned emergency visit to a physician’s office for a primary diagnosis of heart failure; d) an unplanned emergency visit to a physician's office to initiate or intensify treatment other than augmentation of oral diuretic therapy alone; e) initiation or intensification of heart failure-specific treatment; and / or f) Initiate intravenous therapy.

5. The use according to claim 1, wherein dapagliflozin is administered at 10 mg per day.

6. The use according to claim 1, wherein the improvement in heart failure symptoms is measured by a higher score of the patient on the KCCQ TSS compared to the patient's score before starting treatment with the pharmaceutical composition comprising a therapeutically effective amount of dapagliflozin.

7. The use according to claim 6, wherein the higher score of KCCQ TSS is at least 5 points higher than the score before administration of the pharmaceutical composition comprising a therapeutically effective amount of dapagliflozin.

8. The use according to claim 6, wherein the higher score of KCCQ TSS is at least 10 points higher than the score before administration of the pharmaceutical composition comprising a therapeutically effective amount of dapagliflozin.

9. The use according to claim 6, wherein the higher score of KCCQ TSS is at least 15 points higher than the score before administration of the pharmaceutical composition comprising a therapeutically effective amount of dapagliflozin.

10. The use of claim 1, wherein the improvement in heart failure symptoms is measured by a lower worsening of the patient's score on the KCCQ TSS compared to a regimen in which the patient receives at least one standard heart failure care agent alone.

11. The use according to claim 1, wherein the use satisfies at least one of the following conditions: a) the use results in a hazard ratio of less than 1 for the time to the first composite endpoint of heart failure hospitalization, cardiovascular death, or urgent heart failure visit in the patient relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; b) the use results in a hazard ratio of time to first composite endpoint of heart failure hospitalization, cardiovascular death, or urgent heart failure visit in the patient that is statistically nominally less than 1 relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; c) the use results in a hazard ratio of about 0.73 at 18 months for the time to the first composite endpoint of heart failure hospitalization, cardiovascular death, or urgent heart failure visit in the patient relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; d) the use results in a 95% confidence interval for the hazard ratio for time to the first composite endpoint of heart failure hospitalization, cardiovascular death, or urgent heart failure visit in the patient of approximately 0.60 to 0.88 at 18 months relative to the patient receiving a dosing regimen of at least one standard of heart failure care agent alone; e) the use numerically reduces the absolute risk of a composite endpoint of heart failure hospitalization, cardiovascular death, or urgent heart failure visit in the patient relative to a regimen in which the patient receives at least one standard heart failure care agent alone; f) the use results in a nominally significant reduction in the risk of a composite endpoint of heart failure hospitalization, cardiovascular death, or urgent heart failure visit in the patient relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; g) the use results in a numerical reduction in the composite endpoint of heart failure hospitalization, cardiovascular death, or urgent heart failure visit in the patient relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; h) the use results in a numerically reduced incidence of a composite endpoint of heart failure hospitalization, cardiovascular death, or urgent heart failure visit in the patient relative to a regimen of at least one standard heart failure care agent alone; i) the use results in a hazard ratio of less than 1 for the time to cardiovascular death in the patient relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; j) the use results in a hazard ratio of time to cardiovascular death in the patient that is nominally significantly less than 1 relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; k) the use results in a hazard ratio of about 0.85 at 18 months for the time to cardiovascular death in the patient relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; l) the use results in a 95% confidence interval for the hazard ratio for time to cardiovascular death in the patient of about 0.66 to 1.10 at 18 months relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; m) the use results in a hazard ratio of less than 1 for the time to the first composite endpoint of heart failure hospitalization or urgent heart failure visit in the patient relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; n) the use results in a hazard ratio of time to the first composite endpoint of heart failure hospitalization or urgent heart failure visit in the patient that is statistically nominally less than 1 relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; o) the use results in a hazard ratio of about 0.62 at 18 months for the time to the first composite endpoint of heart failure hospitalization or urgent heart failure visit in the patient relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; p) the use results in a 95% confidence interval for the hazard ratio for the time to the first composite endpoint of heart failure hospitalization or urgent heart failure visit in the patient of approximately 0.48 to 0.80 at 18 months relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; q) the use results in a hazard ratio of less than 1 for time to first heart failure hospitalization in the patient relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; r) the use results in a hazard ratio of time to first HF hospitalization in the patient that is statistically nominally less than 1 relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; s) the use results in a hazard ratio of about 0.63 at 18 months for time to first HF hospitalization in the patient relative to the patient receiving a dosing regimen of at least one standard HF care agent alone; t) the use results in a 95% confidence interval for a hazard ratio for time to first HF hospitalization in patients of about 0.48 to 0.81 at 18 months relative to patients receiving a dosing regimen of at least one standard HF care agent alone; u) the use results in a reduction in the mean change in NT-proBNP levels in patients over 8 months from the start of treatment relative to patients receiving a dosing regimen of at least one standard of care heart failure agent alone; and / or v) the use results in a reduction in the mean change in NT-proBNP levels in patients over 8 months of initiation of treatment by -278 pg / ml relative to patients receiving a dosing regimen of at least one standard heart failure care agent alone.

12. The use according to claim 1, wherein the use satisfies at least one of the following conditions: a) the use results in a hazard ratio of less than 1 for the time to a composite endpoint of heart failure hospitalization or cardiovascular death in the patient relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; b) the use results in a hazard ratio of time to a composite endpoint of heart failure hospitalization or cardiovascular death in the patient that is statistically nominally less than 1 relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; c) the use results in a hazard ratio of about 0.73 at 18 months for the composite endpoint of heart failure hospitalization or cardiovascular death in the patient relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; d) the use results in a 95% confidence interval for a hazard ratio for time to a composite endpoint of heart failure hospitalization or cardiovascular death in the patient of about 0.60 to 0.89 at 18 months relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; e) the use numerically reduces the absolute risk of a composite endpoint of hospitalization for heart failure or cardiovascular death in the patient relative to a regimen in which the patient receives at least one standard heart failure care agent alone; f) the use results in a nominally significant reduction in the incidence of a composite endpoint of heart failure hospitalization or cardiovascular death in a patient relative to a regimen in which the patient receives at least one standard heart failure care agent alone; g) the use results in a numerical reduction in a composite endpoint of heart failure hospitalization or cardiovascular death in the patient relative to a patient receiving a dosing regimen of at least one standard heart failure care agent alone; h) the use results in a numerically reduced incidence of a composite endpoint of heart failure hospitalization or cardiovascular death in the patient relative to a regimen in which the patient receives at least one standard heart failure care agent alone.

13. The use according to claim 1, wherein the use satisfies at least one of the following conditions: a) the use results in a hazard ratio of less than 1 for time to all-cause mortality in the patient relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; b) the use results in a hazard ratio of time to all-cause mortality in the patient that is nominally significantly less than 1 relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; c) the use results in a hazard ratio for time to all-cause mortality in the patient of about 0.88 at 18 months relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; d) the use results in a 95% confidence interval for the hazard ratio for time to all-cause mortality in the patient of about 0.70 to 1.12 at 18 months relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; e) the use numerically reduces the absolute risk of all-cause mortality relative to patients receiving a regimen of at least one standard heart failure care agent alone; f) the use results in a nominally significant reduction in the incidence of all-cause mortality in the patient relative to a regimen in which the patient receives at least one standard heart failure care agent alone; g) the use results in a numerical reduction in all-cause mortality relative to a patient receiving a dosing regimen of at least one standard heart failure care agent alone; h) the use results in a numerically reduced incidence of all-cause mortality in the patient relative to a patient receiving a dosing regimen of at least one standard heart failure care agent alone.

14. The use according to claim 1, wherein the use satisfies at least one of the following conditions: a) the use results in an incidence rate ratio of less than 1 for the total number of hospitalizations for heart failure events (first and recurrent) and CV death in the patient relative to a regimen in which the patient receives at least one standard heart failure care agent alone; b) the use results in an incidence rate ratio of the total number of hospitalizations for heart failure events (first and recurrent) and CV death in the patient that is nominally significantly less than 1 relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; c) the use results in an incidence rate ratio of about 0.73 at 18 months for the total number of hospitalizations for heart failure events (first and recurrent) and CV death in the patient relative to the patient receiving a dosing regimen of at least one standard heart failure care agent alone; d) the use results in an incidence rate ratio of about 0.59 to 0.91 at 18 months for the total number of hospitalizations for heart failure events (first and recurrent) and CV death in patients relative to patients receiving a dosing regimen of at least one standard heart failure care agent alone; e) the use numerically reduces the absolute risk of the total number of hospitalizations for heart failure events (first and recurrent) and CV death in the patient relative to a regimen in which the patient receives at least one standard heart failure care agent alone; f) the use results in a nominally significant reduction in the incidence of the total number of hospitalizations for heart failure events (first and recurrent) and CV death in patients relative to patients receiving a dosing regimen of at least one standard heart failure care agent alone; g) the use results in a numerical reduction in the total number of hospitalizations for heart failure events (first and recurrent) and CV deaths in the patient relative to a regimen in which the patient receives at least one standard heart failure care agent alone; h) the use results in a numerical reduction in the incidence of the total number of hospitalizations for heart failure events (first and recurrent) and CV death in patients relative to patients receiving a dosing regimen of at least one standard heart failure care agent alone.

15. The use according to any one of claims 1 to 14, wherein the dapagliflozin is in the form of a (S)-propylene glycol ((S)-PG) solvate having the following structure:

16. The use according to claim 1, wherein the dapagliflozin reduces new-onset diabetes.

17. The use according to claim 1, wherein the dapagliflozin reduces the incidence of hyperkalemia.